1. Neuroscience

Repressor element 1-silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells

  1. Haiwei Zhang
  2. Hongchen Li
  3. Mingshun Lu
  4. Shengnan Wang
  5. Xueya Ma
  6. Fei Wang
  7. Jiaxi Liu
  8. Xinyu Li
  9. Haichao Yang
  10. Fan Zhang
  11. Haitao Shen
  12. Noel J Buckley
  13. Nikita Gamper
  14. Ebenezer N Yamoah  Is a corresponding author
  15. Ping Lv  Is a corresponding author
  1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, China
  2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, China
  3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, China
  4. Lab of Pathology, Hebei Medical University, China
  5. Department of Psychiatry, University of Oxford, United Kingdom
  6. Kavli Institute for Nanoscience Discovery, University of Oxford, United Kingdom
  7. Faculty of Biological Sciences, University of Leeds, United Kingdom
  8. Department of Physiology and Cell Biology, School of Medicine, University of Nevada, United States
  9. The Hebei Collaboration Innovation Center for Mechanism, Diagnosis and Treatment of Neurological and Psychiatric Disease, Hebei Medical University, China
https://doi.org/10.7554/eLife.76754
Share this article
Cite this article
  1. Haiwei Zhang
  2. Hongchen Li
  3. Mingshun Lu
  4. Shengnan Wang
  5. Xueya Ma
  6. Fei Wang
  7. Jiaxi Liu
  8. Xinyu Li
  9. Haichao Yang
  10. Fan Zhang
  11. Haitao Shen
  12. Noel J Buckley
  13. Nikita Gamper
  14. Ebenezer N Yamoah
  15. Ping Lv
(2022)
Repressor element 1-silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells
eLife 11:e76754.
https://doi.org/10.7554/eLife.76754
  2. Download BibTeX
  3. Download .RIS

Abstract

Repressor element 1-silencing transcription factor (REST) is a transcriptional repressor that recognizes neuron-restrictive silencer elements in the mammalian genomes in a tissue- and cell-specific manner. The identity of REST target genes and molecular details of how REST regulates them are emerging. We performed conditional null deletion of Rest (cKO), mainly restricted to murine hair cells (HCs) and auditory neurons (aka spiral ganglion neurons [SGNs]). Null inactivation of full-length REST did not affect the development of normal HCs and SGNs but manifested as progressive hearing loss in adult mice. We found that the inactivation of REST resulted in an increased abundance of Kv7.4 channels at the transcript, protein, and functional levels. Specifically, we found that SGNs and HCs from Rest cKO mice displayed increased Kv7.4 expression and augmented Kv7 currents; SGN’s excitability was also significantly reduced. Administration of a compound with Kv7.4 channel activator activity, fasudil, recapitulated progressive hearing loss in mice. In contrast, inhibition of the Kv7 channels by XE991 rescued the auditory phenotype of Rest cKO mice. Previous studies identified some loss-of-function mutations within the Kv7.4-coding gene, Kcnq4, as a causative factor for progressive hearing loss in mice and humans. Thus, the findings reveal that a critical homeostatic Kv7.4 channel level is required for proper auditory functions.

Editor's evaluation

Genetic forms of deafness are a major health challenge. This study deciphers the cochlear roles of repressor element 1–silencing transcription factor (REST), a gene involved in the DFNA27 dominant form of deafness, using the mouse as a model system. This study provides evidence for a pathophysiological mechanism of deafness and shows how genes involved in different forms of deafness may interact together. The article will be interesting to readers who work in the field of hearing research, REST regulation, or Kv7.4 regulation.

https://doi.org/10.7554/eLife.76754.sa0

Introduction

The repressor element 1-silencing transcription factor (REST), also known as neuronal restriction-silencing factor (NRSF), is a transcriptional repressor that binds a specific 21 bp consensus sequence named repressor element 1 (RE-1) (Chong et al., 1995; Schoenherr and Anderson, 1995). REST recruits multiple chromatin remodeling factors through its DNA-binding domain to form a repressor complex, ultimately repressing the transcription of target genes (Ooi and Wood, 2007). REST is expressed in embryonic stem cells, neural stem cells, and non-neural cells during embryogenesis. It maintains embryonic stem cells' pluripotency and promotes stem cell differentiation and neuronal development, which are essential for neuronal diversity, plasticity, and survival (Chen et al., 1998; Sun et al., 2005). In non-neuronal cells, REST maintains a non-neuronal cell gene expression pattern by suppressing the expression of neural-related genes through histone deacetylation, chromatin remodeling, and methylation (Chen et al., 1998). Recent studies suggest that the role of REST expands beyond neuronal development. There are nearly 2000 genes containing predicted REST binding sites (Bruce et al., 2004; Johnson et al., 2007; Seki et al., 2014), and up to 90% of these REST target genes are tissue- and cell-type-specific (Bruce et al., 2009; Hohl and Thiel, 2005). As a result, REST is involved in numerous physiological and pathological processes. For example, REST was suggested to have a neuroprotective role in Alzheimer’s disease (Lu et al., 2014). Upregulation of REST in peripheral somatosensory neurons was shown to contribute to the development of neuropathic pain (Rose et al., 2011; Zhang et al., 2018; Zhang et al., 2019). In addition, longevity in humans was associated with REST upregulation and repression of neuronal excitation (Zullo et al., 2019).

Cochlear hair cells (HCs) and spiral ganglion neurons (SGNs) play essential roles in transmitting auditory signals. Inner hair cells (IHCs) convert mechanical stimuli into electrochemical signals transmitted to and conducted along auditory nerve fibers (Ó Maoiléidigh and Ricci, 2019; Fettiplace, 2017; Yu and Goodrich, 2014). In contrast, outer hair cells (OHCs) act as mechanical amplifiers that enhance the sensitivity to weak sounds in the cochlea (Dallos et al., 2008; Liberman et al., 2002). SGNs are at the bottleneck between HCs and the brain, preserving sound information’s amplitude, frequency, and temporal features (Meyer and Moser, 2010; Taberner and Liberman, 2005). Since HCs and SGNs in the mature mammalian cochlea do not regenerate, their damage or dysfunction leads to permanent sensorineural hearing loss (Fujioka et al., 2015).

A recent study reported that the exon 4-containing REST splice variant (Rest4) is expressed in cochlear HCs and that its deletion results in abnormally high REST expression and is associated with DFNA27 hearing loss (Nakano et al., 2018). Yet, the role of the full-length REST in hearing is still unknown. We generated a mouse model with REST conditionally knocked out in the cochlea. We show that REST is expressed in cochlear HCs and SGNs of adult mice and that the conditional deletion of REST in these cells results in progressive hearing loss. No detectable loss of cochlear HCs and SGNs was found at P1–P14 during development, but significant degeneration of OHCs and SGNs was detected at 3 months. Examination of the function of HCs and SGNs showed that Kv7.4 channel expression was upregulated, reducing SGNs’ excitability. Consistently, administration of the compound with Kv7.4 channel activator activity, fasudil, caused hearing loss in wild-type mice, while inhibition of the Kv7 channels by XE991 rescued the hearing phenotype of Rest cKO mice. In summary, our results demonstrate that REST is essential for hearing and its deficiency causes upregulation of Kv7.4 channels contributing to the dysfunction of SGNs and HCs and deafness in mice.

Results

REST is expressed in SGNs and HCs and is required for hearing

To examine the role of REST in hearing, we first examined the expression of REST in the cochlea of 1-month-old wild-type (WT) mice. We found that REST was abundantly expressed in cochlear SGNs, IHCs, and OHCs but absent in Rest cKO mice as determined by immunofluorescence staining (Figure 1A) and single-cell PCR (Figure 1—figure supplement 1A). Rest and its splice form Rest4 were detected by single-cell RT-PCR in OHCs on P13, IHCs on P20, and SGNs on P40 in WT mice (Figure 1B). We then investigated whether specific deletion of Rest in the cochlea affected mouse hearing. Mice with homozygous intronic LoxP sites flanking exon 2 of Rest (Restflox/flox) (Soldati et al., 2012) were crossed with Atoh1-Cre mice (Matei et al., 2005; Yang et al., 2010). The Cre was expressed in HCs and SGNs and some supporting cells in the inner ear (Matei et al., 2005; Yang et al., 2010), resulting in the specific knocking out of Rest in these cells (Figure 1C). The genotypes of the pups were identified using PCR analysis (Figure 1D).

Figure 1 with 2 supplements see all
Download asset Open asset
Repressor element 1-silencing transcription factor (REST) expression in the inner ear is essential for hearing.

(A) Expression of REST in spiral ganglion neurons (SGNs) from the apical, middle, and basal cochlea of 1-month-old wild-type (WT) and Rest conditional knockout (cKO) mice. SGNs were stained using anti-REST (red) and anti-Tuj1, a neuron marker (green). The nuclei were stained with DAPI (blue). Scale bar: 20 μm. (B) Single-cell RT-PCR analysis of Rest expression in SGNs of WT mice at P40, outer hair cells (OHCs) at P13, and inner hair cells (IHCs) at P20. (C) Schematic diagram of Rest cKO generation process. Two LoxP sites were inserted into both alleles of REST, flanking the coding sequence of exon 2. Cre recombinase expression is activated by the specific Atoh1 promoter in the cochlea and the exon 2 region between the homodromous LoxP sites, resulting in the loss of REST function cochlea. (D) PCR genotyping of WT and Rest cKO mice using genomic DNA prepared from tail biopsies. Rest cKO mice were identified by two-step PCR, first screening for the Rest-loxP target band and then further identifying for mice containing the Atoh1-Cre target band. (E, F) Auditory brainstem response (ABR) thresholds and click values were measured in WT, Rest +/cKO mice, and Rest cKO mice at 1–2 months old. (G) Morphometry changes in SGNs were observed in WT, Rest +/cKO, and Rest cKO mice. Scale bar: 50 μm. (H) Representative ABR waveforms in response to clicking (90–30 dB) sound pressure levels in 1- and 3-month-old WT and Rest cKO mice. (I, J) ABR threshold statistics of WT and Rest cKO mice at 1 month (I) and 3 months (J) of age in response to pure tone stimuli (8–32 kHz). Data are means ± SEM, **p<0.01, ***p<0.001.

Figure 1—source data 1

Expression of REST in the inner ear and the hearing function in WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig1-data1-v2.zip

The auditory function of 1–2-month-old WT and Rest cKO animals was evaluated by measuring auditory brainstem responses (ABR) to click and pure-tone stimuli. Both heterozygous (Rest +/cKO) and homozygous Rest knockout (Rest cKO) mice exhibited a significant increase in the ABR threshold (as compared to WT), indicating hearing impairment (Figure 1E–G). There was no statistical difference in hearing impairment between Rest +/cKO and Rest cKO mice. Therefore, we used Rest cKO mice in subsequent experiments.

We evaluated the hearing function of 1- and 3-month-old Rest cKO mice. Compared to age-matched WT mice, both 1- and 3-month-old Rest cKO mice displayed a significantly elevated ABR threshold across all frequencies (Figure 1H–J). Furthermore, in 3-month-old Rest cKO mice, there were no detectable ABRs at 24 kHz, 28 kHz, and 32 kHz, suggesting complete hearing loss in the high-frequency range (Figure 1J). These results indicate that Rest cKO mice undergo progressive hearing loss. Similar results were observed in Rest +/cKO mice (Figure 1—figure supplement 1B and C). ABRs typically consist of five positive waves: wave I represents activity from the auditory nerve, while waves II–V represent neural transmission within the central auditory system. ABR latencies and amplitudes of waves I and II were measured with a click stimulus and a 16 kHz pure-tone stimulus in WT and Rest cKO mice to assess hearing sensitivity and functional integrity of the auditory nerve. Compared to WT mice, 1-month-old Rest cKO mice had stimulus level-dependent decrease in amplitude and increase in latency of wave I. This effect was even more pronounced in 3-month-old mice, indicating a gradual decline in the hearing status of Rest cKO mice (Figure 1—figure supplement 2A–D). Similarly, we observed a significant difference in the amplitude and latency of wave II between WT and Rest cKO mice at 1 and 3 months of age (Figure 1—figure supplement 2E–H). These results indicate a deficit in auditory neural processing in Rest cKO mice; this decline in hearing status ensues from early sound processing at the levels of HCs and SGNs.

Degeneration of SGNs and HCs is observed in 3-month-old but not in 1-month-old Rest cKO mice

To investigate the cause of hearing loss induced by REST deficiency, we examined the morphology of SGNs and HCs in Rest cKO mice. Immunofluorescence and HE staining revealed no apparent morphological abnormalities or SGN and HC loss in the apical, middle, and basal turns in P1–14 and 1-month-old Rest cKO cochleas (Figure 2B and F, Figure 2—figure supplement 1). However, SGN and HC degeneration was observed in the cochlea of 3-month-old mice (Figure 2C–E and G–L). These data indicate that SGNs and HCs loss might be responsible for hearing loss in 3-month-old Rest cKO mice but perhaps not in 1-month-old mice.

Figure 2 with 1 supplement see all
Download asset Open asset
Degeneration of spiral ganglion neurons (SGNs) and hair cells (HCs) is observed in 3-month-old Rest conditional knockout (cKO) mice but not in 1-month-old mice.

(A, B) Morphometry changes in SGNs were observed in the apical, middle, and basal cochlea of 1- and 3-month-old wild-type (WT) and Rest cKO mice. Scale bar: 200 μm in (A) and 50 μm in (B). (C–E) SGNs were quantified in all three regions of the cochlea. (F) Myo7a-stained HCs from 1- and 3-month-old WT and Rest cKO mice. Scale bar: 20 μm. (G–I) Quantification of outer hair cells (OHCs) at the cochlea’s apical middle and basal regions in WT and Rest cKO mice (1M and 3M). (J–L) Quantification data of inner hair cells (IHCs) in WT and Rest cKO mice. Data are means ± SEM, **p<0.01, ***p<0.001.

Figure 2—source data 1

Original images and quantitative data of SGNs and HCs in WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig2-data1-v2.zip

Excitability of SGNs is decreased in Rest cKO mice

Given the lack of apparent indications of morphological alterations in SGNs and HCs in 1-month-old Rest cKO mice, we explored whether dysfunction of SGNs or HCs resulted in the early onset of hearing impairment in these mice. We first examined the excitability of SGNs in Rest cKO and WT mice. The whole-cell patch-clamp technique recorded action potentials (APs) in SGNs. A 0.4 nA current injection evoked a single spike in the apical SGNs of the cochlea in WT mice (Figure 3A). In contrast, 27.8% (P14), 63.2% (1-month-old), and 57.6% (3-month-old) of SGNs from Rest cKO mice failed to produce APs, indicating reduced excitability of apical SGNs in Rest cKO mice (Figure 3B).

Figure 3
Download asset Open asset
Reduced excitability of spiral ganglion neurons (SGNs) in Rest conditional knockout (cKO) mice.

(A) Representative traces show spike patterns of SGNs in the apical and basal cochlea, recorded with whole-cell patch clamps. Spikes were generated by 0.4 nA current injection. (B) Pie charts illustrating the percentage abundance of the different spike patterns of SGNs in wild-type (WT) and Rest cKO mice. (C–F) The resting membrane potentials (RMPs) (C), action potential thresholds (D), latencies (E), and rheobases (F) were recorded from apical and basal SGNs in WT and Rest cKO mice at P14, 1, and 3 months. Data are means ± SEM, *p<0.05, **p<0.01,***p<0.001.

Figure 3—source data 1

Data of excitability of SGNs in WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig3-data1-v2.zip

SGNs at the base of the cochlea in P14, 1-, and 3-month-old WT mice could generate multiple AP patterns, including single AP (1 spike), phasic (2–6 spikes), and tonic (>6 spikes) (Figure 3A). In contrast, the proportions of SGNs generating multiple spikes decreased in Rest cKO mice, and many basal SGNs did not generate even a single AP. The ratios of these ‘silent’ neurons were 11.7, 35.3, and 32.8% in P14, 1-, and 3-month-old Rest cKO mice, respectively. These recordings indicate that the excitability of SGNs at the base of the cochlea in Rest cKO mice was reduced (Figure 3B). Additionally, the Rest cKO mice displayed hyperpolarized resting membrane potentials (RMP) in apical SGNs in 1- and 3-month-old mice and basal SGNs at P14 (Figure 3C). The AP thresholds in apical and basal SGNs were significantly increased in 3-month-old Rest cKO mice and apical SGNs at P14 compared to WT mice (Figure 3D). AP latencies were prolonged in SGNs of 1-month-old Rest cKO mice, and rheobase currents were increased in P14, 1-, and 3-month-old Rest cKO mice compared to WT mice (Figure 3E and F). Collectively, these data demonstrate that REST deficiency alters the electrophysiological properties of SGNs in mice, rendering the neurons less excitable.

Kv7.4 is upregulated in the inner ear of Rest cKO mice

Ion channels are the key membrane proteins controlling neuronal excitability. They are responsible for setting the RMP and maintaining aspects such as the APs' duration, threshold, and firing frequency. Therefore, we explored which ion channels are involved in the reduced excitability of SGNs induced by REST deficiency. We focused on ion channels that are known to regulate the excitability of mouse SGNs (Reijntjes and Pyott, 2016) and contain RE-1 sites: key Nav and Kv1 subunits, Kv4.3, HCN1-2, and Kv7 (Mucha et al., 2010; Reijntjes and Pyott, 2016; Uchida et al., 2010b; Figure 4A). We compared the changes in the expression of these channels in the cochlea of WT and Rest cKO mice. As shown in Figure 4A and B, Kv7.4 channel mRNA and protein levels were significantly elevated in the cochlea of Rest cKO mice, while expression of other tested channels was not significantly affected. Further immunofluorescence results showed increased expression of Kv7.4 channel proteins in both HCs and SGNs (Figure 4C–H).

Figure 4
Download asset Open asset
Kv7.4 expression is increased in spiral ganglion neurons (SGNs) and hair cells (HCs) of Rest conditional knockout (cKO) mice.

(A, B) Kcnq4 expression is significantly increased in the cochlea of Rest cKO mice at the mRNA and protein (Kv7.4) levels as determined by real-time PCR (A) and Western blotting (B). (C–F) Immunofluorescence shows increased Kv7.4 (red) expression in the SGNs from apical, middle, and basal cochlea in Rest cKO mice. Scale bar: 20 μm in (C, G). (G, H) Kv7.4 expression increases in HCs of Rest cKO mice. Data are means ± SEM, ***p<0.001.

Figure 4—source data 1

Data for Kv7.4 expression in SGNs and OHCs in WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig4-data1-v2.zip

Upregulation of Kv7.4 caused a decrease in SGNs’ excitability in Rest cKO mice

Kv7.4 channels belong to the Kv7 channel family and are important components of Kv7 or ‘M-type’ neuronal K+ currents. To determine whether increased Kv7.4 channel expression causes upregulation of channel function, we recorded Kv7 channel currents in the SGNs of WT and Rest cKO mice. SGNs were held at –20 mV, then hyperpolarized to –60 mV for 500 ms with a square voltage pulse before returning to holding potential. The deactivating K+ current amplitude was calculated by subtracting the current amplitude measured at 10 ms before the end of the voltage step to –60 mV from the current amplitude measured at 10 ms after the onset of this voltage step, as ‘a-b’ or ‘c-d’ shown in Figure 5A1. The Kv7 currents were identified as the deactivation current component, blocked by the Kv7 channel blocker XE991 (3 μM), which was calculated as (a-b) – (c-d) (Figure 5A1). The K+ currents recorded from SGN often displayed a degree of rundown. Thus, the Kv7 current component in these recordings may have been underestimated.

Figure 5 with 2 supplements see all
Download asset Open asset
Increased Kv7 currents in the spiral ganglion neurons (SGNs) of Rest conditional knockout (cKO) mice.

(A) Whole-cell Kv7 currents were recorded in wild-type (WT) and Rest cKO SGNs. Representative Kv7 currents were calculated as XE991-sensitive currents upon voltage step from –20 mV to –60 mV. Arrowheads indicate the points at which XE99-sensitive currents were measured (A1). (B) Time course of outward K+ current inhibition by XE991 (3 μM). (C) Comparison of outward K+ current at –20 mV in individual SGNs from the apex (black) and base (red) of the cochlea in the absence (basal) and presence of XE991 (3 μM). (D, E) Summary data show that XE991-sensitive currents (Kv7 current) density is significantly increased in the apical and basal SGNs of 1- and 3-month-old Rest cKO mice compared to WT mice. Data are means ± SEM, *p<0.05, **p<0.01, ***p<0.001.

Figure 5—source data 1

Data of Kv7.4 channel currents recorded in SGNs of WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig5-data1-v2.zip

Representative Kv7 currents and time course of K+ currents inhibited by XE991 recorded in SGNs of P14, 1-, and 3-month-old WT mice are shown in Figure 5A and B, respectively. The presence of XE991-sensitive currents (Kv7 currents) in SGNs was demonstrated by measuring the K+ current density of individual SGNs at –20 mV before (basal) and after the application of XE991 (3 μM) (Figure 5C). We found no significant upregulation of Kv7 current density in the SGNs of P14 mice compared to that in WT mice, while Kv7 current density was dramatically increased in the SGNs at the apex and base of 1- and 3-month-old Rest cKO mice (Figure 5D and E). The capacitances of SGNs from P14, 1-, and 3-month-old WT mice were 14.47 ± 4.33 pF, 15.09 ± 5.31 pF, and 15.19 ± 5.32 pF, and capacitances of SGNs from P14, 1-, and 3-month-old Rest cKO mice were 14.37 ± 4.62 pF, 14.94 ± 4.74 pF, and 15.24 ± 3.33 pF.

Kv7.2 and Kv7.3 also contribute to Kv7 channel currents in many neurons, which are also expressed in SGNs (Jin et al., 2009). To determine whether Kv7.2 and Kv7.3 are involved in the upregulation of Kv7 channel currents, we examined the mRNA levels of Kv7.2 and Kv7.3 in the cochlea of WT and Rest cKO mice using real-time PCR. As shown in Figure 4A, the expression levels of Kv7.2 and Kv7.3 were not significantly different between WT and Rest cKO mice. Further immunofluorescence staining confirmed that the expression of Kv7.2 and Kv7.3 channels remained unchanged in the SGNs of Rest cKO mice (Figure 5—figure supplement 1). These data indicate that deletion of cochlear REST upregulates Kv7.4 channels rather than Kv7.2 and Kv7.3 in SGNs. The results were unexpected as deletion of REST was shown to upregulate Kv7.2 in mouse sensory neurons (Zhang et al., 2019), possibly suggesting that additional factors contribute to cell-type-specific regulation of Kv7 channels by REST.

To further confirm the inhibitory effect of REST on Kv7.4, we overexpressed REST in CHO cells stably expressing Kv7.4 channels and observed a significant decrease in Kv7.4 current density (Figure 5—figure supplement 2). The Western blot results confirmed that overexpression of REST significantly reduced the protein expression level of Kv7.4 channels in CHO cells (Figure 5—figure supplement 2), indicating that REST is responsible for the reduced Kv7.4 currents by inhibiting Kv7.4 protein expression.

Upregulation of Kv7.4 results in dysfunction of OHCs in Rest cKO mice

Kv7.4 is the only Kv7 family member reported to be expressed in OHCs so far and is necessary to maintain the electrophysiological properties of OHCs and their functions (Johnson et al., 2011; Marcotti and Kros, 1999; Perez-Flores et al., 2020). We first recorded Kv7 currents in the OHCs of P10–14 WT and Rest cKO mice. Whole-cell K+ currents were recorded from OHCs, and the XE991-sensitive currents denoted hereafter as Kv7-mediated currents are shown in Figure 6A–E. As with SGNs, Kv7 channel currents were significantly increased in the OHCs of Rest cKO mice (Figure 6F).

Figure 6
Download asset Open asset
Increased Kv7 currents in the outer hair cells (OHCs) of Rest conditional knockout (cKO) mice.

(A) Representative current traces recorded from the OHCs of P13 wild-type (WT) mice and the resulting traces after application of XE991. K+ currents were obtained from a holding potential of –84 mV and stepped up from –144 to +34 mV, with 10 mV increments (left panel). (B) Current density–voltage curves are shown before and after XE991 (3 μM) application in WT mice. (C) Similar data was obtained from the OHCs of Rest cKO mice in the control condition, and after XE991 (3 μM), current traces were applied. (D) Current density–voltage curves are shown before and after the application of XE991 in Rest cKO mice. (E) The difference current traces, which represent the XE991-sensitive currents. (F) Difference current density–voltage curve obtained from OHCs in WT and Rest cKO mice. (G, H) Distortion product otoacoustic emission (DPOAE) threshold measurement of 1- and 3-month-old WT and Rest cKO mice. Data are means ± SEM, *p<0.05, **p<0.01.

Figure 6—source data 1

Data of Kv7.4 channel currents recorded in OHCs of WT and Rest cKO mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig6-data1-v2.zip

Subsequently, we measured the distortion product otoacoustic emissions (DPOAEs). DPOAEs depend on active processes in the cochlea, which are linked to the normal function of OHCs (Dallos, 1992). DPOAEs detect low-level sounds produced by functional OHCs and emitted back to the ear canal. We demonstrated that DPOAE thresholds were significantly increased in Rest cKO mice (Figure 6G and H), indicating a decline in the function of OHCs; such an effect is consistent with the upregulation of Kv7.4 in OHCs.

Pharmacological activation of Kv7 channels impairs hearing in mice

To verify that upregulation of Kv7.4 channel functions results in hearing loss in vivo, we administered fasudil (i.p., 10 mg/kg and 20 mg/kg, every 2 days) to WT mice and evaluated their hearing function. Fasudil is a Rho-related protein kinase (ROCK) inhibitor (Shi and Wei, 2013), which was recently shown to directly and selectively (amongst other Kv7 subunits) activate Kv7.4-containing channels (Zhang et al., 2016). ABR was measured before and 14 and 28 days after fasudil administration (Figure 7A). The hearing thresholds of mice in the 10 mg/kg and 20 mg/kg fasudil-treated groups were significantly higher on day 28, indicating hearing impairment (Figure 7B). Analysis of the amplitudes and latencies of ABR waves I and II revealed shorter amplitudes with click and pure-tone stimulation and longer latencies with pure-tone stimulation after fasudil treatment, suggesting that fasudil may trigger auditory nerve processing dysfunction at the level of HCs and SGNs (Figure 7—figure supplement 1).

Figure 7 with 2 supplements see all
Download asset Open asset
Kv7.4 channel activation induced hearing impairments.

(A) Timeline for auditory brainstem response (ABR) testing and drug treatment. Fasudil was administered to 6–8-week-old wild-type (WT) mice intraperitoneally at 10 mg/kg or 20 mg/kg every other day for 28 days. (B) ABR thresholds in control, saline, and fasudil (10 mg/kg, 20 mg/kg) treatment groups on days 0, 14, and 28. (C, D) Summary data show increased Kv7 current density in the apical and basal spiral ganglion neurons (SGNs) of fasudil (10 mg/kg, 20 mg/kg)-treated mice. (E) Summary of spike patterns recorded in SGNs from control, saline, and fasudil (10 mg/kg, 20 mg/kg)-treated mice. (F–I) Resting membrane potentials (RMPs), action potential thresholds, latencies, and rheobases were recorded from mice’s apical and basal SGNs. Data are means ± SEM, *p<0.05, **p<0.01, ***p<0.001.

Figure 7—source data 1

Data of the effect of fasudil on hearing function and excitability of SGNs in WT mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig7-data1-v2.zip

We subsequently determined whether the loss of SGNs or HCs induced hearing impairment. We demonstrated that all groups of mice displayed normal cochlear morphology with no loss of SGNs and HCs (Figure 7—figure supplement 2), suggesting that fasudil treatment did not alter the morphology or number of HCs and SGNs.

Next, we assessed the effect of fasudil on cochlear cell function. We examined the effects of fasudil on Kv7 currents in SGNs and their excitability. Kv7 current density in SGNs in both the apex and base was significantly increased in the fasudil-treated groups (Figure 7C and D). Additionally, SGN excitability was dramatically reduced (Figure 7E), manifesting as hyperpolarized RMPs, elevated AP thresholds, prolonged AP latencies, and elevated AP rheobases (Figure 7F–I).

Kv7 channel blocker XE991 rescues hearing loss in Rest cKO mice

To demonstrate that the upregulation of Kv7.4 channels caused by REST deficiency leads to deafness in mice, we investigated whether blocking Kv7.4 channels could rescue hearing loss in Rest cKO mice. We tested the hearing function of Rest cKO mice before and after administering XE991, a Kv7 channel inhibitor (Figure 8A) and found that the ABR thresholds of Rest cKO mice were significantly reduced following treatment with 0.25 mg/kg XE991. We further observed an increase in amplitude and a decrease in latencies of ABR waves I and II, indicating an improvement in hearing (Figure 8B and C, Figure 8—figure supplement 1A–D). Moreover, the ABR thresholds of mice in the XE991 0.5 mg/kg treatment group were also significantly lower at low frequencies (4–8 kHz), with no differences in the amplitude and latency of waves I and II, indicating a partial improvement in hearing (Figure 8B and C, Figure 8—figure supplement 1E–H). Reduction of XE991 efficacy at a higher dose may mean additional on- or off-target side effects of the drug at a higher dosage.

Figure 8 with 1 supplement see all
Download asset Open asset
Kv7 channel blocking rescues hearing of Rest conditional knockout (cKO) mice.

(A) Timeline for auditory brainstem response (ABR) testing and drug treatment. XE991 was administered to 1-month-old Rest cKO mice intraperitoneally at 0.25 mg/kg or 0.5 mg/kg. (B) Representative ABR waveforms in response to clicking (90–30 dB) sound pressure levels in the saline and XE991-treated groups mice. (C) ABR thresholds in the saline and XE991 (0.25, 0.5 mg/kg) treatment groups. Data are means ± SEM, *p<0.05, **p<0.01, ***p<0.001.

Figure 8—source data 1

ABR data in control and XE991-treated mice.

https://cdn.elifesciences.org/articles/76754/elife-76754-fig8-data1-v2.zip

Discussion

REST, a transcriptional repressor, plays a dominant role in neural development and differentiation. Emerging evidence indicates that REST is an important player in the developed nervous system, including recognized roles in chronic pain development (Rose et al., 2011; Uchida et al., 2010a, Zhang et al., 2018; Zhang et al., 2019) and aging (Cheng et al., 2022; Lu et al., 2014; Zullo et al., 2019). However, the role of REST in hearing is still unknown. Here, we generated conditional inactivation of Rest in the cochlea. We found that specific deletion of Rest resulted in enhanced Kv7.4 channel expression in HCs and SGNs and increased Kv7 currents in both cell types, leading to reduced SGN excitability and compromised HC function, with both effects resulting in progressive hearing loss in mice. Consistently, administration of the compound with Kv7.4 channel activator activity, fasudil, caused hearing loss in WT mice, while the Kv7 channel inhibitor XE991 modestly rescued the hearing deficit of Rest cKO mice.

Several loss-of-function mutations of Kv7.4 in humans and animal models were reported to cause gradual degeneration of HCs and SGNs, resulting in an autosomal-dominant form of non-syndromic progressive hearing loss (DFNA2) (Coucke et al., 1999; Jentsch et al., 1990; Kharkovets et al., 2006; Kim et al., 2011; Kubisch et al., 1999). Our results suggest that 1-month-old Rest cKO mice showed no degeneration of SGNs and HCs, which indicates that enhanced Kv7.4 expression/current can also lead to hearing loss. Our findings reinforce a hypothesis whereby a specific range of basal Kv7.4 functional expression is necessary for good hearing. A reduction or increase outside of this safety range causes cochlear dysfunction. It is currently unclear whether the upregulation of Kv7.4 and degeneration of SGNs and HCs, observed in 3-month-old Rest cKO mice, are related phenomena; this will require further investigation. Importantly, we identified the transcriptional suppressor REST as an essential regulator of hearing in mice.

The mammalian Rest gene is 20–30 kb long and consists of five exons and four introns. Rest pre-mRNA can generate multiple splice variants with alternative splicing. Rest4, a result of the alternative splicing of exon 4, was reported to reduce the repressive activity of REST, which is present in the HCs of P1–P7 mice (Nakano et al., 2018). Heterozygous deletion of exon 4 resulted in the gain of function of REST, leading to HC degeneration and deafness, which is associated with DFNA27 hearing loss (Nakano et al., 2018), suggesting that Rest4 is necessary for HC development and hearing.

Here, we generated cochlea-specific Rest knockout mice using Atoh1-Cre mice crossed with Rest exon 2-flox mice to determine whether REST deficiency affects hearing. Because exon 2 is an exon essential for a functional REST protein, its knockout results in the loss of function of the full-length and all alternatively spliced REST variants. Hence, our results demonstrate that a total loss of functional REST in the cochlea causes hearing loss, suggesting that a full-length REST is vital for HC and SGN functions. REST was first identified in the chick cochlea by RT-PCR in 2002 (Roberson et al., 2002). The REST splice variant was recently demonstrated in immature HCs in mice (Nakano et al., 2018). Our study found that REST is expressed in adult HCs and immature and mature SGNs.

Kv7.4 channel is a voltage-dependent K+ channel encoded by the KCNQ4 gene. It belongs to the Kv7 K+ channel family containing five Kv channels, Kv7.1–Kv7.5 (Jentsch, 2000; Jones et al., 2021). The Kv7 channels are widely distributed in the neurons, heart, vascular smooth muscle cells, and cochlea (Brueggemann et al., 2014; Delmas and Brown, 2005; Jentsch, 2000; Kharkovets et al., 2000; Neyroud et al., 1997). In the cochlea, Kv7.4 is mainly expressed in the OHCs, IHCs, and SGNs (Beisel et al., 2005; Dierich et al., 2020; Kharkovets et al., 2000). When expressed in heterologous expression systems, Kv7.4 channels conduct slowly activating and deactivating currents that do not inactivate (i.e., as shown in Figure 5—figure supplement 2). We noted that the XE991-sensitive currents recorded from OHCs had faster kinetics than those expected from heterologously expressed Kv7.4 homo-tetramers (Figure 6E). Hence, we suggest that OHCs may contain endogenous factors or modulators that alter the Kv7.4 channel kinetics. On the other hand, currents recorded from SGNs had an ‘M-like’ slow-kinetics component, especially in neurons from Rest cKO mice (Figure 5). Loss-of-function mutations in KCNQ4 cause DFNA2 sensorineural deafness (Coucke et al., 1999; Kharkovets et al., 2006). Our results demonstrate that upregulation of Kv7.4 channels also leads to hearing loss in mice, presumably by silencing SGNs and inducing dysfunction in HCs.

In this study, we did not directly measure the binding of REST to Kcnq4, but direct binding has been reported before (Iannotti et al., 2013). REST regulates the expression of a variety of ion channel genes, including genes coding for HCN channels (Kuwahara, 2013; McClelland et al., 2011), Nav1.2 channels (Armisén et al., 2002; Pozzi et al., 2013), Kv7.2/Kv7.3 channels (Mucha et al., 2010; Rose et al., 2011), and T-type Ca2+ channels (van Loo et al., 2012). Although some ion channel-related REST target genes were also expressed in the cochlea, our results showed that REST deletion only significantly upregulated Kv7.4 channels in SGNs and HCs (amongst genes tested here, see Figure 4A). REST deletion specifically upregulates Kcnq4 but not other RE1-containing ion channel-related genes in the cochlea that remain to be investigated. However, it is worth noting that different RE1 sites bind REST with different affinities (Ooi and Wood, 2007); hence, at least some potentially REST-targeted genes may not be tonically suppressed (and, thus, not affected by REST deletion). In addition, REST could suppress additional regulators of other genes. Therefore, the outcome of REST deletion may not necessarily affect the expression of all RE1-containing genes in the same way. Moreover, the genes involved may be cell- and tissue-specific.

To verify that upregulation of Kv7.4 channels can cause hearing loss, we treated mice with the compound with Kv7.4 channel activator activity, fasudil. Although fasudil was initially described as a ROCK inhibitor (Shi and Wei, 2013), recently, Li et al., 2017 found that fasudil selectively increased Kv7.4 channel currents in dopaminergic (DA) neurons in the ventral tegmental area (VTA). Moreover, Zhang et al. revealed that fasudil selectively activated Kv7.4 channels in vascular smooth muscles (Zhang et al., 2016). It was further demonstrated that fasudil has a selective direct opening effect on Kv7.4 channels without significantly affecting other members of the Kv7 channel family (Zhang et al., 2016). We observed increased Kv7 channel currents in SGNs in mice 28 days after recurrent fasudil administration, accompanied by deafness.

It should be noted that Kv7.4 channels are also expressed in neurons of the dorsal nucleus of the cochlea and the hypothalamus nucleus in the central auditory pathway (Kharkovets et al., 2000). Thus, fasudil could influence hearing by affecting Kv7.4 channels in these neurons. The amplitude and latency of ABR waves, which represent the process of neural transmission in the auditory system, were measured to elucidate further the exact site of action of systemic fasudil on hearing. Fasudil administration alters waves I and II of the ABR characteristics, indicating the involvement of HCs and SGNs (Figure 7—figure supplement 1). The actions of fasudil are reversible upon acute application (Zhang et al., 2016). Under the current conditions where the drug was administered chronically, we conceive that long-term and irreversible effects may ensue.

XE991, a Kv7 channel blocker, was used to demonstrate that upregulation of Kv7.4 channels caused by REST defects is involved in deafness in mice. Our results indicated that at low concentrations (0.25 mg/kg), XE991 significantly rescued the hearing of Rest cKO mice, while at high concentrations (0.5 mg/kg), XE991 had a more modest effect on restoring the hearing of these mice. As a certain number of Kv7.4 channels is necessary to regulate cell excitability and thus maintain hearing in mice, their up- or downregulation beyond the basal range of expression would impact hearing. Therefore, we hypothesize that 0.25 mg/kg XE991 could appropriately inhibit the overexpressed Kv7.4 channels in Rest cKO mice, restoring them to a ‘safe’ range. In contrast, 0.5 mg/kg XE991 may overinhibit Kv7.4 channels beyond the scope in which Kv7.4 channels perform their normal function and ultimately fail to improve hearing in mice. Other on- or off-target side effects of higher doses of XE991 also cannot be excluded.

In conclusion, our findings revealed that a critical homeostatic level of functional expression of the Kv7.4 channel is required to maintain proper auditory functions. REST is necessary for hearing through regulating such functional expression of Kv7.4. The study contributes to an understanding of the essential functions of REST in the auditory system and provides new insight into the potential future treatments of hearing disorders associated with the Kv7.4 channel.

Methods

Animals

All experimental animal protocols were performed following the Animal Care and Ethical Committee of Hebei Medical University (Shijiazhuang, China). The mice were bred and housed under a 12:12 light–dark cycle. To generate Atoh1-Cre: Restflox/flox conditional knockout mice (Rest cKO), Restflox/flox mice (Soldati et al., 2012) were crossed with Atoh1-Cre mice (Jackson Laboratories, Bar Harbor, ME, stock no. 011104). Genotyping of the mouse tails and cochlear tissues was performed using the primers listed in Source data 1. All experimental animal protocols were performed following the Animal Care and Ethical Committee of Hebei Medical University (Shijiazhuang, China; 01644).

Auditory Brainstem Responses (ABRs) and Distortion Product Otoacoustic Emissions (DPOAE)

ABR measurements were performed as previously described (Shen et al., 2018). Briefly, mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). Three electrodes were inserted subcutaneously at the vertex of the head (reference), ipsilateral mastoid (recording), and contralateral rear leg of the mice (ground). At 8, 12, 16, 20, 24, 28, and 32 kHz, click or tone stimuli were emitted from 20 dB with an attenuation interval of 5 dB. ABRs were measured using a System III workstation (Tucker Davis Technologies, Alachua, FL) in an IAC BioSigRP Sound booth (GM Instruments, Irvine, UK). The hearing threshold was defined as the lowest sound intensity required to generate a reproducible ABR waveform. Latencies of ABR waves Ⅰ and Ⅱ were measured at 70 dB click and 70 dB, 16 kHz pure-tone stimulus, respectively. Amplitudes were calculated as the peak-to-peak amplitude from the P1 or P2 peak to the next negative trough.

The DPOAE at 2f1-f2 was elicited from test mice using BioSig-RP software and a TDT system (Tucker-Davis Technologies). Five frequency points of 4, 8, 16, 28, and 32 kHz were selected to measure the 2f1-f2(f2/f1 = 1.2) to predict the auditory thresholds. Hearing thresholds were defined as the averaged signal for each identified frequency tested and compared with the corresponding frequency in the controls.

Cell culture

SGNs were isolated from the mouse’s inner ears following a detailed procedure outlined in a previous study (Lv et al., 2010). Mice at various ages were humanely sacrificed, and the temporal bones were removed. The dissecting solution contained minimum essential medium (MEM) with Hank’s Balanced Salt Solution (HBSS) (Invitrogen) supplemented with 0.2 g/L kynurenic acid, 10 mM MgCl2, 2% fetal bovine serum (FBS; v/v), and glucose (6 g/L). The SGN tissue was dissected and split into two segments: the apex and the base across the modiolar axis. The two-segment tissue was digested separately in an enzyme mixture containing collagenase type I (1 mg/mL) and DNase (1 mg/mL) at 37°C for 15 min. After gentle trituration and centrifugation (2000 rpm for 5 min) in 0.45 M sucrose, the cell pellets were reconstituted in 900 μL of culture media (Neurobasal A, supplemented with 2% B27 [v/v], 0.5 mM l-glutamine, 100 units/mL penicillin; Invitrogen). The suspension containing the SGNs was filtered through a 40 μm cell filter and planted on glass coverslips pretreated with 0.5 mg/mL poly d-lysine (Sigma-Aldrich) and 1 mg/mL laminin (Sigma-Aldrich). SGNs were kept in culture for 24–48 hr before electrophysiological recordings to allow for the detachment of Schwann cells from the soma.

A Chinese hamster ovary (CHO) cell line stably expressing human Kv7.4 (GenBank accession numbers: NM_004700.4) channels (Inovogen Tech, China) was maintained in MEM with 10% FBS, a 1% penicillin-streptomycin mixture (Gibco), and 20 μg/mL puromycin at 37°C with 5% CO2. CHO cells were cultured in MEM supplemented with 10% FBS without antibiotics for 12–24 hr before transfection. The pIRES2-REST-EGFP (Sangon Biotech, Shanghai, China) or the pIRES2-EGFP (Sangon Biotech) plasmid constructs were transiently transfected into CHO cells alone or in combination, at a total amount of 600 ng/well, using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. Inovogen Tech performed authentication of purchased cell lines. All cell lines were certified mycoplasma-free as per our monthly contamination testing.

Electrophysiology

Whole-cell voltage-clamp recordings from SGNs were performed at room temperature using a Multiclamp 700 B amplifier (Molecular Devices, Sunnyvale, CA, USA). Signals were filtered at 2 kHz with a low-pass Bessel filter and digitized at ≥20 kHz using a 12-bit acquisition system, Digidata 1332 (Axon Instruments), and pClamp 10.7 software (Molecular Devices). Patch pipettes were pulled from borosilicate glass capillaries and heat polished to a tip resistance of 3–4 MΩ. The pipette solution contained (in mM) 112 KCl, 2 MgCl2, 0.1 CaCl2, 10 HEPES, 1 EGTA, 5 K2ATP, and 0.5 Na-GTP, adjusted to a pH of 7.35 with potassium hydroxide (KOH). The bath solution contained 130 mM NaCl, 5, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, and 10 mM glucose, adjusted to a pH of 7.4 with NaOH. To record the K+ currents, SGNs were held at –20 mV, then hyperpolarized to –60 mV for 500 ms with a square voltage pulse before returning to holding potential. The deactivating K+ current amplitude was calculated by subtracting the current amplitude measured at 10 ms before the end of the voltage step to –60 mV from the current amplitude measured at 10 ms after the onset of this voltage step. XE991 was purchased from Tocris Bioscience, and all other chemicals were purchased from Sigma.

Whole-cell current-clamp recordings from SGNs were conducted using the same pipette solution in the voltage-clamp experiment. To measure the Kv7.4 channel currents in CHO cells stably expressing Kv 7.4 channels, pipettes were filled with internal solutions containing (in mM) 145 KCl, 1 MgCl2, 10 HEPES, 5 EGTA, 5 K2ATP, adjusted to a pH of 7.35 with KOH. The external solution contained 140 mM NaCl, 3 KCl, 1.5 MgCl2, 2 CaCl2, 10 HEPES, and 10 mM glucose and was adjusted to 7.4 pH with NaOH. Kv7.4 channel current traces were generated with 2.5 s depolarizing voltage steps from a holding potential of –80 mV to a maximal value of +40 mV in 10 mV increments. Currents were measured with capacitance and series resistance compensation (nominally 70–90%).

To record K+ currents in OHCs, apical cochlear turns of P10–P14 mice were dissected in a solution containing (in mM) 144.6 NaCl, 5.5KCl, 1 MgCl2, 0.1 CaCl2, 0.5 MgSO4, 10.2 HEPES, and 3.5 l-glutamine, adjusted to a pH of 7.2 with NaOH. The pipette solution contained (in mM) 142 KCl, 3.5 MgCl2, 1 EGTA, 2.5 MgATP, 0.1 CaCl2, 5 HEPES, adjusted to a pH of 7.4 with KOH. The external solution contained (in mM) 145 NaCl, 5.8 KCl, 0.9 MgCl2, 1.3 CaCl2, 0.7 NaH2PO4, 10 HEPES, and 5.6 d-glucose, adjusted to a pH of 7.4 with NaOH. To record K+ currents in OHCs in a whole-cell configuration, OHCs were held at –84 mV with step voltages ranging from –144 mV to 34 mV, with 10 mV increments. Recordings were performed at room temperature using Axon patch 700 B (Molecular Equipment, USA) amplifiers. Data acquisition was controlled by Clampex10.7 (Molecular Equipment) and a Digidata 1440A A-D converter (Molecular Equipment).

Whole-mount preparation of SGNs and HCs

The mice were anesthetized, and the cochleae were fixed in 4% paraformaldehyde (PFA) overnight at 4°C and then decalcified in 10% EDTA (#798681, Sigma, Darmstadt, Germany) in PBS for 2–3 days at 4°C. The EDTA solution was changed daily. Decalcified cochleae were processed using a sucrose gradient and embedded in an OCT compound (Tissue-Tek) for cryo-sectioning. The specimens were sliced into 10 μm sections for study.

For HC preparation, the SGNs, Reissner’s membrane, and the most basal cochlear segments were removed after fixation with 4% PFA for 2 hr, followed by decalcification in 10% EDTA for 3 days at 4°C. HC preparations were used for immunofluorescence staining.

Cell count

To evaluate SGN morphometry and density, cochlear sections were stained with hematoxylin and eosin (HE). Rosenthal’s canal was divided into the apex, middle, and base regions. SGN density from these three regions was measured using Image-Pro Plus 5.1. Five to six sections per cochlea per animal were analyzed, and six mice were used in each group. Cells displaying Myo7A labeling were quantified as the number of positive cells per 100 μm of basilar membrane length from the apex, middle, and base for HC counts.

Immunofluorescence staining

Specimens were simultaneously permeabilized and blocked with 10% goat serum in 0.1% TritonX-100 and 0.1% BSA for 30 min at 37°C and then labeled with primary antibodies overnight at 4°C. The primary antibodies used in this study were mouse anti-Kv7.4 antibodies (#ab84820, Abcam, Cambridge, UK; 1:100), rabbit anti-REST antibodies (#22242-1-AP, Proteintech, USA; 1:200), mouse anti-Tuj1 (#801202, BioLegend, CA; 1:100), rabbit anti-Myo7A antibodies (#25-6790, Proteus BioSciences, CA; 1:50), and Phalloidin-iFluor 555 (#ab176756, Abcam). For detection, the specimens were incubated with Alexa 488-conjugated and Alexa 568-conjugated secondary antibodies (#115-545-003, 115-165-003, 111-545-003, 111-165-003, Jackson ImmunoResearch, PA; 1:400) for 2 hr at room temperature and then stained with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI, #D9542, Sigma) for 10 min at room temperature. After washing with PBS, ProLong Gold Antifade Mount (# P36934, Invitrogen, CA) was used to mount the samples. Sections were visualized using a confocal fluorescent microscope (Leica Microsystems, Wetzlar, Germany). Images were analyzed with Leica LAS AF Lite and processed using ImageJ and Photoshop CS5 (Adobe, San Jose, CA).

Single-cell RT-PCR

Cochleae were dissected from adult WT mice. SGNs or HCs were aspirated into a patch pipette using a patch-clamp system under the microscope. The electrode tip was then quickly broken into an RNase-free PCR tube containing 1 µL of oligo dT primers (50 µM), 1 µL of dNTP mixture (10 mM), 2 µL of RNase-free water. The mixture was incubated in the water bath at 65℃ for 5 min and then placed on ice for 1 min. Single-strand cDNA was synthesized from cellular mRNA by supplementing with 1 µL of PrimeScript II RTase (200 U/µL), 0.5 µL of RNase Inhibitor (40 U/µL), 2 µL of 5× PrimeScript II buffer, and 1.5 µL of RNase Free H2O and then incubating the mixture at 55℃ for 50 min followed by 85℃ for 5 min. The protocol was performed at 95℃ for 5 min, followed by 35 cycles (95℃ for 50 s, 59℃ for 50 s, 72℃ for 50 s) and final elongation at 72℃ for 10 min by adding ‘outer’ primers (Source data 1). The PCR product was identified by 2% agarose gel electrophoresis. The reverse transcription kit was purchased from Takara-Clontech (6210A, Invitrogen), and the PCR kits were obtained from Promega (M7122, Madison).

Western blotting

Cochlear tissues (five mice per sample) were homogenized, and cells were lysed in a RIPA solution containing 0.1% SDS, 50 mM Tris (pH 7.4), 1 mM EDTA (pH 8.0), 1% sodium deoxycholate, 1% TritonX-100, and 200 μM of phenylmethanesulfonyl fluoride (PMSF). The lysis mixture was centrifuged at 13,800 × g for 30 min at 4°C. The supernatant was removed, and the protein concentration was determined using a BCA Protein Assay Kit (#23235, Thermo, CA). Equal amounts of protein (40 μg) were resolved by SDS-PAGE and transferred to a PVDF membrane (#IPVH00010, Millipore, MA). Membranes were blocked with 1× TBST containing 5% dry milk for 2 hr at room temperature and probed with the following antibodies: anti-Kv7.4 antibodies (#ab84820, Abcam; 1:500), anti-REST antibodies (#ab21635, Abcam; 1:1000), or anti-tubulin beta-III antibodies (#MMS-435P, BioLegend; 1:10,000) overnight at 4°C. Then, fluorescent secondary conjugated IgG (#IRDye 800CW goat anti-rabbit IgG [H+L]; #IRDye 800CW goat anti-mouse IgG [H+L], LI-COR Biosciences, NE; 1:10,000) was applied for 90 min at room temperature. All Western blots were quantified using Image Studio software (IS, LI-COR Biosciences).

Quantitative real-time PCR

Total RNA from mouse cochleae was extracted using an RNA Extraction Kit according to the manufacturer’s instructions (#9767, TaKaRa, Japan). The extracted RNA concentration was measured using a NanoDrop 2000 spectrophotometer (#ND-LITE, Thermo, DE), and 1000 ng of total RNA was reversed-transcribed using PrimeScript reverse transcriptase (#RR036Q, TaKaRa, China). The synthesized cDNA was used as a template to perform quantitative real-time (qRT)-PCR with TB Green Premix Ex Taq (#RR420Q, TaKaRa) in a Bio-Rad Real-Time PCR System (Bio-Rad Laboratories, CA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control to normalize the relative mRNA abundance of each cDNA. The relative mRNA expression levels were calculated using the standard formula 2-∆∆Ct. All the primers used in this study were designed using Primer Premier 6.25 (PREMIER Biosoft International, CA) and synthesized by Sangon Biotech (Shanghai, China). The primer sequences are shown in Source data 1.

In vivo drug administration

For fasudil administration

6–8-week-old C57 mice were divided into four groups: control, saline, fasudil 10 mg/kg, and fasudil 20 mg/kg. Fasudil was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), dissolved in 0.9% saline, and administered intraperitoneal injection every 2 days for 28 days. Control mice were injected intraperitoneally with the same volume of saline. ABR was recorded before and after treatment with the drug and on days 14 and 28 after treatment to assess hearing function. The cochlea was also removed on day 28 to evaluate the morphological changes of the HCs and SGNs and the functional changes of the SGNs.

For XE991 administration

The 1-month-old Rest cKO mice were divided into three groups: the saline, XE991 0.25 mg/kg, and 0.5 mg/kg. XE991 dihydrochloride was obtained from Abcam and dissolved in 0.9% saline. Mice received a single dose of XE991 (0.25, 0.5 mg/kg) or saline intraperitoneally. ABR was measured in each group of mice before and 30 min after drug administration to characterize the effects of the drug on mouse hearing.

Statistical analysis

All data are presented as the means ± SEM. Statistical analyses were performed using GraphPad Prism 6.0. The Student’s t-test was used to compare data between two groups, and ANOVA was used for multiple comparisons. Proportions of cells displaying distinct electrophysiological properties were analyzed using Fisher’s exact test or Pearson’s chi-square test. *, **, and *** indicate statistically significant results compared to the appropriate controls and indicate p<0.05, p<0.01, and p<0.001, respectively.

Data availability

All data generated or analyzed are included in the source data.

References

    1. Armisén R
    2. Fuentes R
    3. Olguín P
    4. Cabrejos ME
    5. Kukuljan M
    (2002)
    Repressor element-1 silencing transcription/neuron-restrictive silencer factor is required for neural sodium channel expression during development of Xenopus
    The Journal of Neuroscience 22:8347–8351.
    1. Zhang X
    2. An H
    3. Li J
    4. Zhang Y
    5. Liu Y
    6. Jia Z
    7. Zhang W
    8. Chu L
    9. Zhang H
    (2016)
    Selective activation of vascular Kv 7.4/kv 7.5 K (+) channels by fasudil contributes to its vasorelaxant effect
    British Journal of Pharmacology 173:3480–3491.

Decision letter

  1. Tanya T Whitfield
    Reviewing Editor; University of Sheffield, United Kingdom
  2. Kathryn Song Eng Cheah
    Senior Editor; University of Hong Kong, Hong Kong
  3. Radha Kalluri
    Reviewer; University of Southern California, United States
  4. Nicolas Antoine Michalski
    Reviewer; Institut Pasteur, France

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Repressor element 1–silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Tanya Whitfield as the Reviewing Editor and Kathryn Cheah as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Radha Kalluri (Reviewer #2); Nicolas Antoine Michalski (Reviewer #3).

The reviewers have discussed their reviews with one another, and agree that although the work is promising, some revisions (including additional experimental work and important controls) are required to support the conclusions drawn. The Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1. Demonstrate appropriate controls:

– For REST expression in SGNs and hair cells, together with details of the epitope recognised by the antibody

– To ensure RT–PCR amplification products represent those from mRNA rather than genomic DNA, addressing the issues of alternative splicing

2. Address the issue of the expression of Tg(Atoh1–Cre) in supporting cells and SGNs, and the consequences this may have for the REST cKO phenotype.

3. Acknowledge the known functions, specificity and duration of action of fasudil when the compound is first mentioned, discussing any limitations this may have for interpreting the effects of this compound and citing the relevant literature.

4. Provide further analysis and discussion of the effects of REST cKO in addition to the up–regulation of Kv7 currents, clarifying whether (or not) there is any causal link between the hearing loss originating from an alteration of the bioelectrical properties of the sensory cells and the hearing loss originating from cellular deterioration.

5. Perform a more comprehensive analysis of the ABR responses to characterise the hearing status of the various mouse models (REST cKO, XE199–treated and fasudil–treated) at both 1 month and 3 months of age, addressing any distinction between OHC and SGN deficits.

6. Address the list of minor suggestions from the Reviewers, including various corrections concerning the citation of the literature.

The full reviews are appended below and provide more information.

Reviewer #1 (Recommendations for the authors):

Detailed comments:

Related to Figure 1: A number of studies have shown that REST is expressed in nearly all non–neuronal cells where it represses hundreds of neuronally–transcribed genes. In differentiating neurons and hair cells (HCs), REST activity is downregulated. In most neurons, transcriptional repression of Rest is the primary mechanism underlying the downregulation of REST activity. In HCs, regulated splicing of an alternative exon into the Rest mRNA is the main mechanism by which REST activity in suppressed. Based on these, one would expect to find minimal expression of Rest in SGNs; however, Zhang and colleagues show strong REST immunostaining in SGNs (Figure 1A). HCs were not tested for REST protein expression by the authors, but they used single cell RT–PCR to evaluate Rest mRNA expression, and they detected Rest in both HCs and SGNs (Figure 1B). These data should be supported by robust controls. For example, the Rest cKO mice could be used to test the specificity of REST immunostaining in SGNs. A similar experimental design is recommended for testing the expression of REST in HCs. The location of the epitope of the anti–REST antibody within the target protein is also an important (and not provided) piece of information because alternative splicing is predicted to prevent the expression of the C–terminal half of REST (encoded by exon 5) but not the N–terminal half. Notably, Rest contains 5 exons, not 4 exons; the latter number is stated erroneously in the manuscript at multiple places.

Figure 1 related: The authors' single cell RT–PCR data would be more informative if the Rest primers were designed from 2 different exons and not from the same exon (all of the Rest RT–PCR primers are designed from exon 5 in this study). If the primers were designed from different exons, amplification of the genomic DNA could be ruled out. In Figure 1B and Methods, there is no control included to test whether the RT–PCR products are amplicons of mRNA or genomic DNA. The authors' primers are also not suitable to test the splicing of Rest. Using these primers, the generated RT–PCR products will not differ in size regardless of whether the alternative exon of Rest (i.e., exon 4) is spliced into the mRNA or not. Therefore, the generated amplicons cannot indicate whether the expressed mRNA encodes a functional REST protein or a non–functional REST that is "truncated" by the previously described alternative splicing of exon 4 of Rest.

Related to Figure 1–9: Tg(Atoh1–Cre) expression is not completely specific to HCs within the organ of Corti. This is not a problem if the effect of Tg(Atoh1–Cre)–dependent gene deletion is robust (e.g., widespread loss of HCs). In contrast, when the HC loss is mild (like in this study), a significant concern is that Tg(Atoh1–Cre) is expressed in some % of supporting cells (see Figures 6 and 7 in PMID: 16145671). Data in this manuscript do not rule out the possibility that much of the HC loss and hearing loss of Rest cKO mice are caused by the deletion of Rest in some % of supporting cells in the organ of Corti.

Related to Figure 1–9: What % of SGNs express Tg(Atoh1–Cre)?

Related to Figure 1: The authors state that "both heterozygous and homozygous Rest knockout mice showed a significant increase in the ABR threshold (as compared to WT)". The authors analyzed the hearing loss of Rest +/cKO (i.e., heterozygous) mice only at a very early time (i.e., 1–2 months). In this age range, the reported hearing loss is mild and not entirely convincing. The demonstration of hearing loss of Rest +/cKO mice would be an important piece of new information because these mice are potentially useful to model the disorders of human subjects who are heterozygous for REST–inactivating mutations. Therefore, it would be valuable to determine the hearing thresholds (click and pure tone) of Rest +/cKO mice at precise timepoints (at 3 and 4 months) when hearing loss is perhaps more robust than in the 1–2 months age range.

Related to Figure 7: The authors suggest that the Kv7.4 activator effect of fasudil is contrary to its Rho kinase (ROCK) inhibitory activity: "Fasudil was initially described as a Rho–associated protein kinase (ROCK) inhibitor. However, recently Li and colleagues found that fasudil selectively increased Kv7.4 channel currents…" (Discussion section). It is unclear why the authors contrast these two effects of fasudil; both effects are supported by multiple studies: fasudil inhibits ROCK and activates Kv7.4. It seems to be important to state both effects of fasudil at the first mention of this compound in the text.

Related to Figure 7: A previous study reported that the Kv7.4–activating effect of fasudil rapidly diminishes after the washout of this drug (PMID: 27677924). Therefore, it would be important that the authors clarify/discuss the mechanism by which in–vivo administered fasudil could affect K+ currents in SGNs that were cultured for 24–48 h after isolation from fasudil–injected mice (Figure 7C–I).

Figure 5—figure supplement 3 shows that overexpressed REST suppresses the expression of plasmid–encoded Kcnq4 (i.e., Kv7.4) in CHO cells. The Kcnq4–encoding plasmid is not described in the manuscript, and it is unclear whether it contains REST binding sites.

Related to Figure 8 and 9: The strongest presented evidence for the hearing loss–causing effect of abnormally high Kv7.4 expression is the XE991–dependent (partial) rescue of hearing in Rest cKO mice. This is a nice experiment but it does not reveal whether XE991 acts on the cells of interest (HCs and SGNs) and on the protein of interest (i.e., Kv7.4) to achieve the improvement in hearing. Ideally, a genetic approach should be used to support the Kv7.4–related conclusion of the study.

Reviewer #2 (Recommendations for the authors):

Progressive hearing loss and cellular deterioration: As indicated above, I found the argument that progressive loss and deterioration of the sort seen in 3 month REST kno as being due to loss of Kv7 to be less convincing. I would have found this second point to be more convincing if the experiments with Kv7 current enhancer fasudil had also shown cellular deterioration like that in the REST knockouts. The data presented in the supplementary figures show that this is not the case, at least not over the timeline of the present experiments. Perhaps the deterioration would take longer than the 28 days over which fasudil was administered but no data was presented to argue this point. Alternatively, knocking out REST may do more than enhance Kv7 currents. More careful handling of this issue is needed.

I also found the term 'hearing loss' in reference to the elevated ABR and DPOAE thresholds to be somewhat unsatisfying. The term does not capture the full impact of enhancing Kv7 channels. Indeed, the ABR responses in the REST knockout (1 month) or fasudil enhanced Kv7 model are robust, with large peaks and multiple waves clearly visible, albeit with elevated thresholds. I wonder, for example, if the desensitized cochlea (with elevated thresholds) has a compressed dynamic range, greater synchrony, and shorter latencies? Similarly, in the case with Kv7 channels blocked, what are the broad response features of the 'sensitized' cochlea. I found this aspect of the data to be interesting but unaddressed. I would have liked to see a more complete analysis of the ABR waves amplitude and latency as a function of stimulus intensity to determine if there is also a difference in the level dependence that would better indicate the hearing status of these mouse models.

Overall, the experiments are nicely done and the data is presented clearly. However, I found the use of extensive figure supplements with minimal description to be confusing. The going back and forth between the main and supplement figures took away from the otherwise clear presentation of data. The authors should consider integrating the necessary figure supplements into the main figures and reducing the number of supplementary figures to those that are essential.

Reviewer #3 (Recommendations for the authors):

Recommendations to be addressed:

– The whole paragraph 125–137 is very confusing in the wording between knock–out mice and conditional knock–out mice. The paragraph should clearly state that:

i) First ABRs were recorded in knock–out mice…

ii) We then recorded in ABRs in conditional knock–out mice…

For instance, the use of "further" in line131 is misleading because it gives the impression we are dealing with the same mice whereas it is not the case. Similarly, what are Rest–homozygous mice? I suppose they are Rest knock–out mice?

– While reading the manuscript, I thought the authors could better insist on the OHC deficits and their relationship to the hearing loss observed. The authors insist very much on the SGN excitability deficits. However, these deficits are already present in 1 month old mice with a similar severity to 3 month old mutant mice although ABR thresholds are still normal at 1 month of age. A likely explanation is rather the DPOAE deficit at three months of age that becomes very strong compared to one month. To better disentangle these phenomena, the authors should analyze the amplitude of wave–1and its timing in Rest cKO mice based on their already acquired data. If these parameters are normal at one month of age, it suggests that the most dramatic phenotype relies on OHCs. Alternatively, wave–1 amplitude could be altered (with normal auditory threshold). In that case, it would show that both the OHC and SGN deficits cumulatively contribute to the hearing impairment. In addition, Kcnq4 playing on the excitability of SGNs, one would expect the timing of wave–1 to be altered.

Depending on these analysis, the authors should better discuss the relative contribution of SGN and OHCs to the auditory phenotype.

– Line373: The statement "the exact site of action of systemic fasudil on hearing requires further elucidation" is not satisfactory. As mentioned earlier, by analyzing wave 1 amplitude and timing in their signal, the authors could specifically address whether fasudil affects HCs and SGNs. Expression of Kv7.4 in the dorsal cochlear nucleus is not expected to affect the ABR signal before Wave–II. Please better discuss this point after analyzing these parameters in the datasets.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Repressor element 1–silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells" for further consideration by eLife. Your revised article has been evaluated by Kathryn Cheah (Senior Editor) and a Reviewing Editor.

The reviewers agree that the manuscript has been improved and will make a valuable contribution to the field. However, there are several remaining issues that need to be addressed, concerning both presentation and interpretation of the data, as outlined below. Please address these concerns, and make sure that any figures used in the rebuttal have also been added to the manuscript, as requested by Reviewer 1. Reviewer 2 also suggests that you may wish to consider moving some of the supplementary material into the main figures. Reviewer 3 also lists a number of typos to be corrected.

Reviewer #1 (Recommendations for the authors):

The authors of this manuscript conclude that genetic inactivation of Rest in hair cells (HCs) and spiral ganglion neurons (SGNs) cause progressive hearing loss by upregulating the expression of Kv7.4 in the two cell types ("Repressor element 1–silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells"). This conclusion is not fully supported by the presented data because the utilized Cre–expressing transgene and some of the key activators/inhibitors in the study are not sufficiently selective to draw a definitive conclusion: (1) The Atoh1–Cre transgene, which was used for the generation of Rest cKO mice in the study, is expressed not only in HCs and SGNs but also in many non–HCs and non–SGNs in the cochlea. This transgene is an excellent tool for many purposes but it is not ideal to determine the effects of SGN/HC specific deletion of Rest on hearing because Rest is expressed in non–HCs and non–SGNs in the hearing organ. (2) Fasudil, which was used for the activation of Kv7.4 in the study, is not a Kv7.4 specific drug; it also binds to (and inhibits) Rho–associated kinases. Thus, the hearing loss of fasudil–injected mice may not be caused by the activation of Kv7.4 but by the inhibition of Rho–associated kinases. (3) XE991 is not a specific inhibitor of Kv7.4, it also inhibits other Kv7 channels. Therefore, it is unclear whether the 10–15 dB improvement in the hearing threshold of XE991–treated Rest cKO mice is caused by the inhibition of Kv7.4 or other Kv7 channels. In summary, the authors' overall conclusion is not entirely convincing because much of their data can be interpreted differently than specified in the manuscript.

In the authors' rebuttal letter (and in the manuscript), one unvalidated data interpretation is used to support another unvalidated interpretation; e.g., in the 3rd answer to reviewer–1, the authors view upregulation of Kv7.4 as a proven cause (as opposed to a 'possible cause') of hearing impairment in Rest cKO mice and use this to state that the hearing loss–relevant deletion of Rest must have been in HCs and/or SGNs because other cochlear cells do not express Kv7.4. This kind of reasoning goes awry easily.

The authors show the ABR thresholds (click and pure tone) of 3–4 months old Rest Het mice in the rebuttal letter but not in the actual manuscript. It would be more useful to the readers if these figure panels were added to the manuscript.

Reviewer #2 (Recommendations for the authors):

1. One of the most interesting aspects of this data set was the patch–clamping data showing enhanced expression of Kv7 currents in Rest cKO mice and the accompanying changes in ABR thresholds at 1M of age, before the onset of obvious cell deterioration. This combined with the experiments showing partial recovery of thresholds using the Kv7 blocker xe991 was the strongest indication that modulation of this particular ion channel was shaping hearing sensitivity, even in the absence of cell death. I had urged the authors to examine the stimulus level–dependent changes in ABR amplitudes and latencies to more fully characterize the hearing status under these different manipulations, hoping that this would help disentangle the impact of cell deterioration versus enhancement of Kv7 currents on the hearing loss phenotype. The authors have partially satisfied that request by providing more ABR data in supplements. However, by providing this analysis at a fixed level and with little further discussion, the authors missed the point…which was to test if there were differences in how the amplitude and latencies grow with stimulus intensity which might have indicated interesting differences in ABR morphology that could be attributed to the increase/decrease in phasic firing in Rest KO or XE199 manipulations. As currently presented in the text, the new ABR data does little to interpret the finding further.

2. Is elevation in Kv7 currents neuroprotective or does this lead to cellular deterioration? Lines 297–306 in the discussion left me with the impression that the authors are arguing that overexpression of Kv7 currents can cause a similar degeneration in cochlear cells as previously shown due to loss of function mutations in Kv7.4. This is perhaps not what the authors intended, because they agreed in their response to my original review that knocking out REST may cause cellular deterioration from multiple pathways and that the fasudil manipulation did not show cellular deterioration. Thus, these studies cannot determine if the cellular degeneration noted in the 3–4 month Rest KO mouse is due to overexpression of Kv7…so the question of whether Kv7 may be neuroprotective cannot be addressed here. I'd recommend a careful revision of this paragraph to avoid conflating elevation in threshold that they may attribute to the enhancement of Kv7 from that which may result from overall cellular damage.

3. The reduced recovery of thresholds for the higher dose of Xe991 is counterintuitive. Why doesn't the higher concentration of XE991 restore thresholds and only at lower frequencies as did the lower concentration? Rather than addressing what seems counterintuitive to me, the authors assert that there is an improvement in threshold and gloss over what seems to be only a partial rescue at the higher dose. Some sort of discussion of this is needed…for example is there some balance between synchrony and excitability that may produce this result? It will be important to do this since the rescue with the blocker is one of the most convincing pieces of data in this study.

4. Problem with the summary figure shown in figure 9. The schematic shows an OHC providing direct input to Type I auditory neurons. Since the input from OHCs to most of the auditory nerve is indirectly coupled through fluid mechanics, this figure could be misconstrued as meaning otherwise. Please revise to avoid such confusion. Alternatively, remove the figure.

5. I still found several supplementary figures to be disruptive to the presentation of the material. Lines 178:186; Figure 3 supplement and Figure 5 supplement 1. I don't see the rationale for discussing the P14 data separately from the 1 Month and 3 Months time points. It seems that it would be natural to integrate all three time points into the same figure. Same comment for Figure 5, why not fold in the P14 data in rather than show a nearly identical representation of that one–time point as a supplement?

https://doi.org/10.7554/eLife.76754.sa1

Author response

Essential revisions:

Reviewer #1 (Recommendations for the authors):

Detailed comments:

Related to Figure 1: A number of studies have shown that REST is expressed in nearly all non–neuronal cells where it represses hundreds of neuronally–transcribed genes. In differentiating neurons and hair cells (HCs), REST activity is downregulated. In most neurons, transcriptional repression of Rest is the primary mechanism underlying the downregulation of REST activity. In HCs, regulated splicing of an alternative exon into the Rest mRNA is the main mechanism by which REST activity in suppressed. Based on these, one would expect to find minimal expression of Rest in SGNs; however, Zhang and colleagues show strong REST immunostaining in SGNs (Figure 1A). HCs were not tested for REST protein expression by the authors, but they used single cell RT–PCR to evaluate Rest mRNA expression, and they detected Rest in both HCs and SGNs (Figure 1B). These data should be supported by robust controls. For example, the Rest cKO mice could be used to test the specificity of REST immunostaining in SGNs. A similar experimental design is recommended for testing the expression of REST in HCs. The location of the epitope of the anti–REST antibody within the target protein is also an important (and not provided) piece of information because alternative splicing is predicted to prevent the expression of the C–terminal half of REST (encoded by exon 5) but not the N–terminal half. Notably, Rest contains 5 exons, not 4 exons; the latter number is stated erroneously in the manuscript at multiple places.

Thank you for your suggestion. We tested the REST protein expression in SGN by immunostaining in WT and Rest cKO mice. Our results showed that Rest was abundantly expressed in SGN of WT mice, while Rest expression was not detected in Rest cKO mice. (Figure 1A) The anti-Rest antibody (proteintech, 22242-1-AP) recognized the C-terminal of REST. We have corrected the exons number of Rest. We thank the reviewer for pointing it out (please see Figure 1C, line 299). Additionally, we provide additional single-cell RT-PCR analyses of Rest in OHCs, and IHCs of WT and Rest cKO mice. The primer sequences: Rest forward: GGT CTG ATC CCG CTC CG, reverse：TGG CCA TAA CTG TAC TCC TCT G (Figure 1—figure supplement 1).

Figure 1 related: The authors' single cell RT–PCR data would be more informative if the Rest primers were designed from 2 different exons and not from the same exon (all of the Rest RT–PCR primers are designed from exon 5 in this study). If the primers were designed from different exons, amplification of the genomic DNA could be ruled out. In Figure 1B and Methods, there is no control included to test whether the RT–PCR products are amplicons of mRNA or genomic DNA. The authors' primers are also not suitable to test the splicing of Rest. Using these primers, the generated RT–PCR products will not differ in size regardless of whether the alternative exon of Rest (i.e., exon 4) is spliced into the mRNA or not. Therefore, the generated amplicons cannot indicate whether the expressed mRNA encodes a functional REST protein or a non–functional REST that is "truncated" by the previously described alternative splicing of exon 4 of Rest.

We agree with your comments. Our primers read from a single exon, and the amplification from the genomic DNA cannot be ruled out. We changed our primers sequence to that used in Nakano's paper (Nakano, Kelly, et al., 2018), designed from exon 3 to exon 5 of Rest. The sequence of the primers is forward 5' CGACACATGCGGACTCATTC 3', and reverse 5' AGAGGCCACATAATTGCACTG 3'. Our results show that two bands were detected in hair cells and SGNs, representing REST and its splice form, Rest4, respectively (Figure 1B). The OHCs were isolated from WT mice at P13, IHCs from mice at P20, and SGNs from mice at P40.

Related to Figure 1–9: Tg(Atoh1–Cre) expression is not completely specific to HCs within the organ of Corti. This is not a problem if the effect of Tg(Atoh1–Cre)–dependent gene deletion is robust (e.g., widespread loss of HCs). In contrast, when the HC loss is mild (like in this study), a significant concern is that Tg(Atoh1–Cre) is expressed in some % of supporting cells (see Figures 6 and 7 in PMID: 16145671). Data in this manuscript do not rule out the possibility that much of the HC loss and hearing loss of Rest cKO mice are caused by the deletion of Rest in some % of supporting cells in the organ of Corti.

As shown in the paper (PMID: 16145671), Tg(Atoh1-Cre) is expressed in some supporting cells. Our study indicates that hearing loss caused by Rest deletion is through upregulation of the Kv7.4 channel. Specific to the reviewer's concern, there is no evidence that Kv7.4 channels are expressed in supporting cells (PMID: 32285007). Therefore, our study suggests that deafness in Rest cKO mice is mainly due to SGNs and HCs dysfunction.

Related to Figure 1–9: What % of SGNs express Tg(Atoh1–Cre)?

The reviewer has posed an important question, but we do not believe the questions addressed in this report can shed light on it.

Related to Figure 1: The authors state that "both heterozygous and homozygous Rest knockout mice showed a significant increase in the ABR threshold (as compared to WT)". The authors analyzed the hearing loss of Rest +/cKO (i.e., heterozygous) mice only at a very early time (i.e., 1–2 months). In this age range, the reported hearing loss is mild and not entirely convincing. The demonstration of hearing loss of Rest +/cKO mice would be an important piece of new information because these mice are potentially useful to model the disorders of human subjects who are heterozygous for REST–inactivating mutations. Therefore, it would be valuable to determine the hearing thresholds (click and pure tone) of Rest +/cKO mice at precise timepoints (at 3 and 4 months) when hearing loss is perhaps more robust than in the 1–2 months age range.

We measured the hearing thresholds of Rest +/- mice at 3 and 4 months. The data showed that the hearing loss was more robust in Rest +/- mice at 3-4 months of age than in mice at 1-2 months.

Author response image 1
Download asset Open asset

Related to Figure 7: The authors suggest that the Kv7.4 activator effect of fasudil is contrary to its Rho kinase (ROCK) inhibitory activity: "Fasudil was initially described as a Rho–associated protein kinase (ROCK) inhibitor. However, recently Li and colleagues found that fasudil selectively increased Kv7.4 channel currents…" (Discussion section). It is unclear why the authors contrast these two effects of fasudil; both effects are supported by multiple studies: fasudil inhibits ROCK and activates Kv7.4. It seems to be important to state both effects of fasudil at the first mention of this compound in the text.

We thank the reviewer for the comment, and we rewrote it as “Fasudil was initially described as a Rho-associated protein kinase (ROCK) inhibitor. Recently Li and colleagues found that fasudil selectively increased Kv7.4 channel currents…” (line 366)

Related to Figure 7: A previous study reported that the Kv7.4–activating effect of fasudil rapidly diminishes after the washout of this drug (PMID: 27677924). Therefore, it would be important that the authors clarify/discuss the mechanism by which in–vivo administered fasudil could affect K+ currents in SGNs that were cultured for 24–48 h after isolation from fasudil–injected mice (Figure 7C–I).

In this paper (PMID: 27677924), fasudil acts on cells with acute perfusion, and its activation of Kv7.4 channels is through interaction with Ile308 in its S6. Moreover, the acute effect of fasudil can be washed out. Besides the acute effects of fasudil as outlined in the report, we surmise that the drug may also have a chronic effect. In the current study, fasudil was injected into mice for 1 month, and the chronic effect of fasudil appeared different from the acute one. We speculate that the effect of fasudil on potassium currents in SGN may be through affecting the translocation or expression of Kv7 channels. We have discussed the subject (lines 381-384).

Figure 5—figure supplement 3 shows that overexpressed REST suppresses the expression of plasmid–encoded Kcnq4 (i.e., Kv7.4) in CHO cells. The Kcnq4–encoding plasmid is not described in the manuscript, and it is unclear whether it contains REST binding sites.

The Kcnq4-encoding plasmid is human-derived (Genebank accession numbers: NM_004700.4). We have included this information in the "method section"(lines 441-442). We also identified that KCNQ4 contains REST binding sites through the JASPAR website (Author response image 2 shows the data from JASPAR).

Author response image 2
Download asset Open asset

Related to Figure 8 and 9: The strongest presented evidence for the hearing loss–causing effect of abnormally high Kv7.4 expression is the XE991–dependent (partial) rescue of hearing in Rest cKO mice. This is a nice experiment but it does not reveal whether XE991 acts on the cells of interest (HCs and SGNs) and on the protein of interest (i.e., Kv7.4) to achieve the improvement in hearing. Ideally, a genetic approach should be used to support the Kv7.4–related conclusion of the study.

We thank the reviewer for the suggestions, and we agree that the evidence is pharmacological and a genetic strategy would have solidified our assertions. The genetic approach may be beyond the scope of the current studies.

Reviewer #2 (Recommendations for the authors):

Progressive hearing loss and cellular deterioration: As indicated above, I found the argument that progressive loss and deterioration of the sort seen in 3 month REST kno as being due to loss of Kv7 to be less convincing. I would have found this second point to be more convincing if the experiments with Kv7 current enhancer fasudil had also shown cellular deterioration like that in the REST knockouts. The data presented in the supplementary figures show that this is not the case, at least not over the timeline of the present experiments. Perhaps the deterioration would take longer than the 28 days over which fasudil was administered but no data was presented to argue this point. Alternatively, knocking out REST may do more than enhance Kv7 currents. More careful handling of this issue is needed.

We agreed with your comments. Since we only administered fasudil for 28 days, we could not determine if the extended administration time caused cellular deterioration. In addition, because REST has many target genes, knocking out Rest may cause cellular deterioration in 3-month-old Rest cKO mice through other pathways.

I also found the term 'hearing loss' in reference to the elevated ABR and DPOAE thresholds to be somewhat unsatisfying. The term does not capture the full impact of enhancing Kv7 channels. Indeed, the ABR responses in the REST knockout (1 month) or fasudil enhanced Kv7 model are robust, with large peaks and multiple waves clearly visible, albeit with elevated thresholds. I wonder, for example, if the desensitized cochlea (with elevated thresholds) has a compressed dynamic range, greater synchrony, and shorter latencies? Similarly, in the case with Kv7 channels blocked, what are the broad response features of the 'sensitized' cochlea. I found this aspect of the data to be interesting but unaddressed. I would have liked to see a more complete analysis of the ABR waves amplitude and latency as a function of stimulus intensity to determine if there is also a difference in the level dependence that would better indicate the hearing status of these mouse models.

Thank you for your comments. We have reanalyzed the amplitude and latency of ABR waves shown in Figure 1—figure supplement 2, Figure 7—figure supplement 2, and Figure 8—figure supplement 1.

We demonstrate from the ABR waveform amplitude and latency assessment that the decline in hearing status ensues from early sound processing at the levels of hair cells and SGNs. The impact of XE991 in ABR waveforms, showing the modest extent of recovery of the hearing status

Overall, the experiments are nicely done and the data is presented clearly. However, I found the use of extensive figure supplements with minimal description to be confusing. The going back and forth between the main and supplement figures took away from the otherwise clear presentation of data. The authors should consider integrating the necessary figure supplements into the main figures and reducing the number of supplementary figures to those that are essential.

Reviewer #3 (Recommendations for the authors):

Recommendations to be addressed:

– The whole paragraph 125–137 is very confusing in the wording between knock–out mice and conditional knock–out mice. The paragraph should clearly state that:

i) First ABRs were recorded in knock–out mice…

ii) We then recorded in ABRs in conditional knock–out mice…

For instance, the use of "further" in line131 is misleading because it gives the impression we are dealing with the same mice whereas it is not the case. Similarly, what are Rest–homozygous mice? I suppose they are Rest knock–out mice?

We apologize for the confusing description. We have corrected the sentence based on the comment. We only used Rest conditional knockout mice, including heterozygotes (Rest +/cKO) and homozygotes (Rest cKO). (lines 128-141)

– While reading the manuscript, I thought the authors could better insist on the OHC deficits and their relationship to the hearing loss observed. The authors insist very much on the SGN excitability deficits. However, these deficits are already present in 1 month old mice with a similar severity to 3 month old mutant mice although ABR thresholds are still normal at 1 month of age. A likely explanation is rather the DPOAE deficit at three months of age that becomes very strong compared to one month. To better disentangle these phenomena, the authors should analyze the amplitude of wave–1and its timing in Rest cKO mice based on their already acquired data. If these parameters are normal at one month of age, it suggests that the most dramatic phenotype relies on OHCs. Alternatively, wave–1 amplitude could be altered (with normal auditory threshold). In that case, it would show that both the OHC and SGN deficits cumulatively contribute to the hearing impairment. In addition, Kcnq4 playing on the excitability of SGNs, one would expect the timing of wave–1 to be altered.

Depending on these analysis, the authors should better discuss the relative contribution of SGN and OHCs to the auditory phenotype.

Thank you for your comments. We reanalyzed the amplitude and latency of wave I in 1-, 3- month-old WT and Rest cKO mice (Figure 1—figure supplement 2). In response to ABR pure-tone 16KHz stimuli at 70 dB SPL, the data revealed lower amplitude and increased wave I latency in both 1- and 3-month-old Rest cKO mice compared to the WT groups (Figure 1—figure supplement 2E, 2F), suggesting cumulative deficits in both OHC and SGN may contribute to hearing impairment.

– Line373: The statement "the exact site of action of systemic fasudil on hearing requires further elucidation" is not satisfactory. As mentioned earlier, by analyzing wave 1 amplitude and timing in their signal, the authors could specifically address whether fasudil affects HCs and SGNs. Expression of Kv7.4 in the dorsal cochlear nucleus is not expected to affect the ABR signal before Wave–II. Please better discuss this point after analyzing these parameters in the datasets.

Thank you for your suggestions. Our data show that fasudil-treated mice exhibit lower wave I and wave II amplitudes in response to ABR click stimulation at 70 dB SPL. In response to a 16 kHz pure tone stimulus at 70 dB SPL, fasudil-treated mice showed lower wave I and wave II amplitudes and increased delay times compared to controls (Figure 7—figure supplement 2). Based on our results we rewrote the discussion. (lines 377-381)

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

The reviewers agree that the manuscript has been improved and will make a valuable contribution to the field. However, there are several remaining issues that need to be addressed, concerning both presentation and interpretation of the data, as outlined below. Please address these concerns, and make sure that any figures used in the rebuttal have also been added to the manuscript, as requested by Reviewer 1. Reviewer 2 also suggests that you may wish to consider moving some of the supplementary material into the main figures. Reviewer 3 also lists a number of typos to be corrected.

Reviewer #1 (Recommendations for the authors):

The authors of this manuscript conclude that genetic inactivation of Rest in hair cells (HCs) and spiral ganglion neurons (SGNs) cause progressive hearing loss by upregulating the expression of Kv7.4 in the two cell types ("Repressor element 1–silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells"). This conclusion is not fully supported by the presented data because the utilized Cre–expressing transgene and some of the key activators/inhibitors in the study are not sufficiently selective to draw a definitive conclusion: (1) The Atoh1–Cre transgene, which was used for the generation of Rest cKO mice in the study, is expressed not only in HCs and SGNs but also in many non–HCs and non–SGNs in the cochlea. This transgene is an excellent tool for many purposes but it is not ideal to determine the effects of SGN/HC specific deletion of Rest on hearing because Rest is expressed in non–HCs and non–SGNs in the hearing organ. (2) Fasudil, which was used for the activation of Kv7.4 in the study, is not a Kv7.4 specific drug; it also binds to (and inhibits) Rho–associated kinases. Thus, the hearing loss of fasudil–injected mice may not be caused by the activation of Kv7.4 but by the inhibition of Rho–associated kinases. (3) XE991 is not a specific inhibitor of Kv7.4, it also inhibits other Kv7 channels. Therefore, it is unclear whether the 10–15 dB improvement in the hearing threshold of XE991–treated Rest cKO mice is caused by the inhibition of Kv7.4 or other Kv7 channels. In summary, the authors' overall conclusion is not entirely convincing because much of their data can be interpreted differently than specified in the manuscript.

We appreciate the reviewer's concerns and agree with most of the above arguments. In the revised manuscript, we have acknowledged these limitations of the approaches taken. Yet, we think that our conclusion that REST deficiency impairs hearing via Kv7.4 upregulation is still the most likely explanation for our results.

1) As mentioned by the reviewer, atoh1 is not only expressed in SGNs and HCs but also in some supporting cells of the organ of Corti. Therefore, to determine whether supporting cells are involved in the hearing loss caused by Rest deletion, we examined the morphology of cochlear cells in 1- and 3-month-old WT and Rest cKO mice by HE staining. We did not find morphological abnormalities in the supporting cells (Data not shown in the manuscript). Although these results cannot completely rule out the possibility that deletion of Rest in support cells may also be involved in deafness, our current data are consistent with the hypothesis that SGNs and HCs are the main cell types contributing to hearing loss in Rest cKO mice.

2) Fasudil, a compound with Kv7.4 channel activator activity, also has an inhibitory effect on Rho-associated kinases. Recently, fasudil was found to prevent neomycin-induced hair cell damage by inhibiting the Rho/Rock signaling pathway, suggesting a cell protective effect as a Rock inhibitor (PMID: 31780893). Moreover, Seiji Kakehata's group did show that ROCK inhibition attenuated cochlear synaptic damage and exerted cytoprotective effects (PMID: 34217338, PMID: 33328888). In our study, injection of fasudil induced hearing loss in mice with increased Kv7 current in SGNs and HCs. Therefore, we reasoned that it might be caused by activation of the Kv7.4 channel rather than inhibition of Rock. Yet, the effect of the Rho pathway cannot be ruled out, which is now acknowledged.

3) In the cochlea, Kv7.1 is expressed in the marginal cells of the stria vascularis, Kv7.2 and Kv7.3 channels are present in the SGNs, and Kv7.4, one of the critical ion channels that regulate auditory signal, is mainly expressed in the SGNs and HCs. Since marginal cells in the stria vascularis have not been found to express Atoh1 (PMID: 20533400), specific deletion of Rest should not affect Kv7.1. Moreover, our results show that Kv7.2 and Kv7.3 in SGNs were not upregulated in Rest cKO mice. Therefore, we reasoned that XE991 improved hearing in Rest cKO mice, likely through inhibition of Kv7.4 channels.

In the authors' rebuttal letter (and in the manuscript), one unvalidated data interpretation is used to support another unvalidated interpretation; e.g., in the 3rd answer to reviewer–1, the authors view upregulation of Kv7.4 as a proven cause (as opposed to a 'possible cause') of hearing impairment in Rest cKO mice and use this to state that the hearing loss–relevant deletion of Rest must have been in HCs and/or SGNs because other cochlear cells do not express Kv7.4. This kind of reasoning goes awry easily.

We apologize for the poor choice of words to answer this question in the previous review comments. As mentioned by the reviewer, Atoh1 is widely expressed in cochlear; deletion of Rest is not limited to HC and SGN but also includes some supporting cells. Although our data suggest that Kv7.4 upregulation in HCs and SGNs is involved in hearing loss in Rest cKO mice, other possibilities exist. We modified the language throughout to acknowledge possible other explanations for the observed effects (we apologize for the apparent circular thinking).

The authors show the ABR thresholds (click and pure tone) of 3–4 months old Rest Het mice in the rebuttal letter but not in the actual manuscript. It would be more useful to the readers if these figure panels were added to the manuscript.

Thank you for your suggestion. We have added this data to figure1—figure supplement 1B, C.

Reviewer #2 (Recommendations for the authors):

1. One of the most interesting aspects of this data set was the patch–clamping data showing enhanced expression of Kv7 currents in Rest cKO mice and the accompanying changes in ABR thresholds at 1M of age, before the onset of obvious cell deterioration. This combined with the experiments showing partial recovery of thresholds using the Kv7 blocker xe991 was the strongest indication that modulation of this particular ion channel was shaping hearing sensitivity, even in the absence of cell death. I had urged the authors to examine the stimulus level–dependent changes in ABR amplitudes and latencies to more fully characterize the hearing status under these different manipulations, hoping that this would help disentangle the impact of cell deterioration versus enhancement of Kv7 currents on the hearing loss phenotype. The authors have partially satisfied that request by providing more ABR data in supplements. However, by providing this analysis at a fixed level and with little further discussion, the authors missed the point…which was to test if there were differences in how the amplitude and latencies grow with stimulus intensity which might have indicated interesting differences in ABR morphology that could be attributed to the increase/decrease in phasic firing in Rest KO or XE199 manipulations. As currently presented in the text, the new ABR data does little to interpret the finding further.

We are very sorry for misinterpreting the previous review comments regarding further analysis of the ABR data. We have re-examined the stimulus level-dependent changes in ABR amplitudes and latencies in Rest cKO, XE991, and fasudil-treated mice. Our results showed that compared to WT mice, 1-month-old Rest cKO mice displayed stimulus level-dependent decreases in amplitudes and increases in latencies of ABR waves I and II, which was more pronounced in 3-month-old mice, suggesting a gradual decline in the hearing status of the Rest cKO mice (figure 1-supplementary figure 2). Fasudil treatment mice displayed shorter amplitudes and longer latencies of waves I and II, suggesting that fasudil might cause auditory nerve processing dysfunction (figure 7-supplementary figure 1). Moreover, increased amplitudes and decreased latencies of ABR waves I and II were shown in Rest cKO mice treated with 0.25 mg/kg XE991, indicating an improvement in their hearing (figure 8-supplementary figure 1).

2. Is elevation in Kv7 currents neuroprotective or does this lead to cellular deterioration? Lines 297–306 in the discussion left me with the impression that the authors are arguing that overexpression of Kv7 currents can cause a similar degeneration in cochlear cells as previously shown due to loss of function mutations in Kv7.4. This is perhaps not what the authors intended, because they agreed in their response to my original review that knocking out REST may cause cellular deterioration from multiple pathways and that the fasudil manipulation did not show cellular deterioration. Thus, these studies cannot determine if the cellular degeneration noted in the 3–4 month Rest KO mouse is due to overexpression of Kv7…so the question of whether Kv7 may be neuroprotective cannot be addressed here. I'd recommend a careful revision of this paragraph to avoid conflating elevation in threshold that they may attribute to the enhancement of Kv7 from that which may result from overall cellular damage.

We thank the reviewer for this suggestion; we have now revised this discussion paragraph. We proposed that upregulation of Kv7.4 channels is an important cause of hearing loss in 1-month-old Rest cKO mice in the absence of degeneration of SGN and HC. In contrast, 3-month-old Rest cKO mice showed significant SGN and HC deficits, and whether the upregulation of Kv7.4 channels caused them requires further experimental evidence in the future (lines 328-340).

3. The reduced recovery of thresholds for the higher dose of Xe991 is counterintuitive. Why doesn't the higher concentration of XE991 restore thresholds and only at lower frequencies as did the lower concentration? Rather than addressing what seems counterintuitive to me, the authors assert that there is an improvement in threshold and gloss over what seems to be only a partial rescue at the higher dose. Some sort of discussion of this is needed…for example is there some balance between synchrony and excitability that may produce this result? It will be important to do this since the rescue with the blocker is one of the most convincing pieces of data in this study.

We thank the reviewer for pointing this out. Yes, our results showed that low concentrations (0.25mg/kg) of XE991 significantly rescued hearing in Rest cKO mice, while higher concentrations (0.5mg/kg) of XE991 can only partially restore hearing in these mice. To discuss this apparent inconsistency, we have added the following Discussion. "XE991, a Kv7 channel blocker, was used to demonstrate that upregulation of Kv7.4 channels caused by REST defects is involved in deafness in mice. Our results indicated that at low concentrations (0.25 mg/kg), XE991 significantly rescued the hearing of Rest cKO mice, while at high concentrations (0.5 mg/kg) XE991 had a more modest effect on restoring the hearing of these mice. As a certain number of Kv7.4 channels is necessary to regulate cell excitability and thus maintain hearing in mice, their up or downregulation beyond the basal range of expression would impact hearing. Therefore, we hypothesize that 0.25 mg/kg XE991 could appropriately inhibit the overexpressed Kv7.4 channels in Rest cKO mice, restoring them to a "safe" range.

In contrast, 0.5 mg/kg XE991 may over-inhibit Kv7.4 channels beyond the range in which Kv7.4 channels perform their normal function and fail to improve hearing in mice completely. Other on- or off-target side effects of higher doses of XE991 also cannot be excluded." (lines 418-430)

4. Problem with the summary figure shown in figure 9. The schematic shows an OHC providing direct input to Type I auditory neurons. Since the input from OHCs to most of the auditory nerve is indirectly coupled through fluid mechanics, this figure could be misconstrued as meaning otherwise. Please revise to avoid such confusion. Alternatively, remove the figure.

We agree with the issue pointed out by the reviewer that the Type I SGN did not form a direct link/synapse to the OHC and that our figure was misleading. Thus, we removed figure 9.

5. I still found several supplementary figures to be disruptive to the presentation of the material. Lines 178:186; Figure 3 supplement and Figure 5 supplement 1. I don't see the rationale for discussing the P14 data separately from the 1 Month and 3 Months time points. It seems that it would be natural to integrate all three time points into the same figure. Same comment for Figure 5, why not fold in the P14 data in rather than show a nearly identical representation of that one–time point as a supplement?

We thank the reviewer for the comments. We have integrated the data for P14, 1-, and 3-month-old mice in the main Figure 3 and Figure 5, respectively.

https://doi.org/10.7554/eLife.76754.sa2

Article and author information

Author details

  1. Haiwei Zhang

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis, Methodology, Writing - original draft
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8209-9395

  2. Hongchen Li

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2639-8726

  3. Mingshun Lu

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  4. Shengnan Wang

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  5. Xueya Ma

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  6. Fei Wang

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  7. Jiaxi Liu

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  8. Xinyu Li

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  9. Haichao Yang

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Data curation, Formal analysis, Methodology
    Competing interests
    No competing interests declared

  10. Fan Zhang

    1. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    2. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    Contribution
    Formal analysis, Funding acquisition, Investigation, Methodology
    Competing interests
    No competing interests declared

  11. Haitao Shen

    Lab of Pathology, Hebei Medical University, Shijiazhuang, China
    Contribution
    Conceptualization, Data curation, Funding acquisition, Investigation
    Competing interests
    No competing interests declared

  12. Noel J Buckley

    1. Department of Psychiatry, University of Oxford, Oxford, United Kingdom
    2. Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom
    Contribution
    Resources, Funding acquisition, Investigation, Writing - original draft, Project administration
    Competing interests
    No competing interests declared

  13. Nikita Gamper

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom
    Contribution
    Resources, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5806-0207

  14. Ebenezer N Yamoah

    Department of Physiology and Cell Biology, School of Medicine, University of Nevada, Reno, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing
    For correspondence
    enyamoah@gmail.com
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9797-085X

  15. Ping Lv

    1. Department of Pharmacology, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang, China
    2. Center for Innovative Drug Research and Evaluation, Institute of Medical Science and Health, Hebei Medical University, Shijiazhuang, China
    3. The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, China
    4. The Hebei Collaboration Innovation Center for Mechanism, Diagnosis and Treatment of Neurological and Psychiatric Disease, Hebei Medical University, Shijiazhuang, China
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Methodology, Writing - original draft, Writing - review and editing
    For correspondence
    lping77@hotmail.com
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6271-8865

Funding

National Institute on Deafness and Other Communication Disorders (DC015135)

  • Ebenezer N Yamoah

National Institute on Aging (AG060504-01)

  • Ebenezer N Yamoah

National Institute on Deafness and Other Communication Disorders (DC016099)

  • Ebenezer N Yamoah

National Institute on Aging (P01 AG051443)

  • Ebenezer N Yamoah

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81670939) to PL, the Natural Science Foundation of Hebei Province of China (H2021206286) to PL, the Department of human resources and social security of Hebei Province for Talents (A202005003) to PL, the central government guiding local funding projects for scientific and technological development(216Z7701G) to PL, and the Science Fund for Creative Research Groups of Natural Science Foundation of Hebei Province (H2020206474) to PL. ENY was supported by grants from the National Institutes of Health (P01 AG051443, R01 DC015135, R01 DC016099, and R01 AG060504-01). NG was supported by the BBSRC International Partnering Award BB/R02104X/1 and the 100 Foreign Experts of Hebei Province program.

Ethics

All experimental animal protocols were performed following the Animal Care and Ethical Committee of Hebei Medical University (Shijiazhuang, China). 01644.

Senior Editor

  1. Kathryn Song Eng Cheah, University of Hong Kong, Hong Kong

Reviewing Editor

  1. Tanya T Whitfield, University of Sheffield, United Kingdom

Reviewers

  1. Radha Kalluri, University of Southern California, United States
  2. Nicolas Antoine Michalski, Institut Pasteur, France

Version history

  1. Received: January 4, 2022
  2. Preprint posted: March 4, 2022 (view preprint)
  3. Accepted: September 16, 2022
  4. Accepted Manuscript published: September 20, 2022 (version 1)
  5. Version of Record published: September 30, 2022 (version 2)

Copyright

© 2022, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 561
    Page views
  • 192
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Haiwei Zhang
  2. Hongchen Li
  3. Mingshun Lu
  4. Shengnan Wang
  5. Xueya Ma
  6. Fei Wang
  7. Jiaxi Liu
  8. Xinyu Li
  9. Haichao Yang
  10. Fan Zhang
  11. Haitao Shen
  12. Noel J Buckley
  13. Nikita Gamper
  14. Ebenezer N Yamoah
  15. Ping Lv
(2022)
Repressor element 1-silencing transcription factor deficiency yields profound hearing loss through Kv7.4 channel upsurge in auditory neurons and hair cells
eLife 11:e76754.
https://doi.org/10.7554/eLife.76754

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Medicine

    Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide

    Thao DV Le, Dianxin Liu ... Julio E Ayala
    Research Article Updated

    The canonical target of the glucagon-like peptide-1 receptor (GLP-1R), Protein Kinase A (PKA), has been shown to stimulate mechanistic Target of Rapamycin Complex 1 (mTORC1) by phosphorylating the mTOR-regulating protein Raptor at Ser791 following β-adrenergic stimulation. The objective of these studies is to test whether GLP-1R agonists similarly stimulate mTORC1 via PKA phosphorylation of Raptor at Ser791 and whether this contributes to the weight loss effect of the therapeutic GLP-1R agonist liraglutide. We measured phosphorylation of the mTORC1 signaling target ribosomal protein S6 in Chinese Hamster Ovary cells expressing GLP-1R (CHO-Glp1r) treated with liraglutide in combination with PKA inhibitors. We also assessed liraglutide-mediated phosphorylation of the PKA substrate RRXS*/T* motif in CHO-Glp1r cells expressing Myc-tagged wild-type (WT) Raptor or a PKA-resistant (Ser791Ala) Raptor mutant. Finally, we measured the body weight response to liraglutide in WT mice and mice with a targeted knock-in of PKA-resistant Ser791Ala Raptor. Liraglutide increased phosphorylation of S6 and the PKA motif in WT Raptor in a PKA-dependent manner but failed to stimulate phosphorylation of the PKA motif in Ser791Ala Raptor in CHO-Glp1r cells. Lean Ser791Ala Raptor knock-in mice were resistant to liraglutide-induced weight loss but not setmelanotide-induced (melanocortin-4 receptor-dependent) weight loss. Diet-induced obese Ser791Ala Raptor knock-in mice were not resistant to liraglutide-induced weight loss; however, there was weight-dependent variation such that there was a tendency for obese Ser791Ala Raptor knock-in mice of lower relative body weight to be resistant to liraglutide-induced weight loss compared to weight-matched controls. Together, these findings suggest that PKA-mediated phosphorylation of Raptor at Ser791 contributes to liraglutide-induced weight loss.

    1. Epidemiology and Global Health
    2. Medicine

    Association between bisphosphonate use and COVID-19 related outcomes

    Jeffrey Thompson, Yidi Wang ... Ulrich H von Andrian
    Research Article Updated

    Background:

    Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate severe COVID-19 could help to address these challenges. The objective of this study was to determine whether prior use of bisphosphonates is associated with reduced incidence and/or severity of COVID-19.

    Methods:

    A retrospective cohort study utilizing payer-complete health insurance claims data from 8,239,790 patients with continuous medical and prescription insurance January 1, 2019 to June 30, 2020 was performed. The primary exposure of interest was use of any bisphosphonate from January 1, 2019 to February 29, 2020. Bisphosphonate users were identified as patients having at least one bisphosphonate claim during this period, who were then 1:1 propensity score-matched to bisphosphonate non-users by age, gender, insurance type, primary-care-provider visit in 2019, and comorbidity burden. Main outcomes of interest included: (a) any testing for SARS-CoV-2 infection; (b) COVID-19 diagnosis; and (c) hospitalization with a COVID-19 diagnosis between March 1, 2020 and June 30, 2020. Multiple sensitivity analyses were also performed to assess core study outcomes amongst more restrictive matches between BP users/non-users, as well as assessing the relationship between BP-use and other respiratory infections (pneumonia, acute bronchitis) both during the same study period as well as before the COVID outbreak.

    Results:

    A total of 7,906,603 patients for whom continuous medical and prescription insurance information was available were selected. A total of 450,366 bisphosphonate users were identified and 1:1 propensity score-matched to bisphosphonate non-users. Bisphosphonate users had lower odds ratios (OR) of testing for SARS-CoV-2 infection (OR = 0.22; 95%CI:0.21–0.23; p<0.001), COVID-19 diagnosis (OR = 0.23; 95%CI:0.22–0.24; p<0.001), and COVID-19-related hospitalization (OR = 0.26; 95%CI:0.24–0.29; p<0.001). Sensitivity analyses yielded results consistent with the primary analysis. Bisphosphonate-use was also associated with decreased odds of acute bronchitis (OR = 0.23; 95%CI:0.22–0.23; p<0.001) or pneumonia (OR = 0.32; 95%CI:0.31–0.34; p<0.001) in 2019, suggesting that bisphosphonates may protect against respiratory infections by a variety of pathogens, including but not limited to SARS-CoV-2.

    Conclusions:

    Prior bisphosphonate-use was associated with dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations. Prospective clinical trials will be required to establish a causal role for bisphosphonate-use in COVID-19-related outcomes.

    Funding:

    This study was supported by NIH grants, AR068383 and AI155865, a grant from MassCPR (to UHvA) and a CRI Irvington postdoctoral fellowship, CRI2453 (to PH).

    1. Medicine

    A single-cell atlas depicting the cellular and molecular features in human anterior cruciate ligamental degeneration: A single cell combined spatial transcriptomics study

    Runze Yang, Tianhao Xu ... Weili Fu
    Tools and Resources Updated

    Background:

    To systematically identify cell types in the human ligament, investigate how ligamental cell identities, functions, and interactions participated in the process of ligamental degeneration, and explore the changes of ligamental microenvironment homeostasis in the disease progression.

    Methods:

    Using single-cell RNA sequencing and spatial RNA sequencing of approximately 49,356 cells, we created a comprehensive cell atlas of healthy and degenerated human anterior cruciate ligaments. We explored the variations of the cell subtypes’ spatial distributions and the different processes involved in the disease progression, linked them with the ligamental degeneration process using computational analysis, and verified findings with immunohistochemical and immunofluorescent staining.

    Results:

    We identified new fibroblast subgroups that contributed to the disease, mapped out their spatial distribution in the tissue and revealed two dynamic trajectories in the process of the degenerative process. We compared the cellular interactions between different tissue states and identified important signaling pathways that may contribute to the disease.

    Conclusions:

    This cell atlas provides the molecular foundation for investigating how ligamental cell identities, biochemical functions, and interactions contributed to the ligamental degeneration process. The discoveries revealed the pathogenesis of ligamental degeneration at the single-cell and spatial level, which is characterized by extracellular matrix remodeling. Our results provide new insights into the control of ligamental degeneration and potential clues to developing novel diagnostic and therapeutic strategies.

    Funding:

    This study was funded by the National Natural Science Foundation of China (81972123, 82172508, 82372490) and 1.3.5 Project for Disciplines of Excellence of West China Hospital Sichuan University (ZYJC21030, ZY2017301).